Confidential Page 1 of 88
PROTOCOL:  1042-TSC-2001
TITLE: A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone 
Treatment (Part A) in Tuberous Sclerosis Complex -related Epi[INVESTIGATOR_59648]-term Treatment (Part B)
DRUG: Ganaxolone
IND: 044,020
SPONSOR : Marinus Pharmaceuticals, Inc.
[ADDRESS_64659]
Radnor, PA [ZIP_CODE] [LOCATION_003]
PRINCIPAL/
COORDINATING
INVESTIGATOR:
[INVESTIGATOR_59649]: Protocol Amendment 2: 11 Jun 2021, Version 3.0
Protocol Amendment 1: 12 May 2020, Version 2.0
Original Protocol: [ADDRESS_64660] party without the express written 
consent of Marinus.
	
		
Study ID: [REMOVED]
This NCT number has been applied to the document for
purposes of posting on Clinicaltrials.gov
 
Confidential Page 2 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
PROTOCOL SIGNATURE [CONTACT_59767]â€™s (Marinus) Approval  
Signature: [CONTACT_1782]: 
 {Note: Signature [CONTACT_59768] } 
 
Investigatorâ€™s Acknowledgement  
I have read this protocol  for Marinus Study 1042-TSC-2001. 
Title:  A Phase 2 Open-label 12-Week Trial of Adjunctive Ganaxolone Treatment (Part A) 
in Tuberous Sclerosis Complex-related Epi[INVESTIGATOR_59650]-term Treatment 
(Part B)  
I have fully discussed the objective(s) of this study and the contents of this protocol with the 
sponsorâ€™s representative.  
I understand that the information in this protocol  is confidential and should not be disclosed, 
other than to those directly involved in the ex ecution or the scientific/ethical review of the study, 
without written authorization from the sponsor.  It is, however, permissible to provide the 
information contained herein to the parent/car egiver/legally authorized guardian (LAR) in order 
to obtain consent to participate. 
I agree to conduct this study according to this prot ocol and to comply with its requirements, 
subject to ethical and safety considerations  and guidelines, and to conduct the study in 
accordance with International Council for Harmonisation guidelines on Good Clinical Practice and with the applicable regulatory requirements. 
I understand that failure to comply with the requirements of the protocol may lead to the 
termination of my participation as an investigator for this study. 
I understand that the sponsor may decide to susp end or prematurely terminate the study at any 
time for whatever reason; such a decision will be communicated to me in writing.  Conversely, 
should I decide to withdraw from execution of the study I will communicate my intention 
immediately in writing to the sponsor. 
Investigator Name [CONTACT_59769]: 
(please hand print or type )  
 
 
Signature:  [CONTACT_1782]:  
	
		


	
[COMPANY_003]
 
Confidential Page 3 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
SUMMARY OF CHANGES FROM PREVIOUS VERSION  
Protocol Amendments 
Summary of Change(s) Since Last Version of Approved Protocol 
  
Amendment Number 
2 Amendment Date  
11 Jun 2021 
Description of Change Section(s) Affected by [CONTACT_59711] (planned)  Study Synopsis  
OL extension  Methodology Part B  
Formatting update  4.1 Inclusion Criteria  
PK sample collection clarification  7.8 Pharmacokinetic Assessments  
Unscheduled visits clarification  7.3.5 Unscheduled visits  
Study design updated  3.1 Study Design and Flow Chart  
Duration of study extended  3.2 Duration and Study Completion 
Definition  
Amendment Number 
1 Amendment Date  
12 May 2020 
Description of Change  Section(s) Affected by [CONTACT_59712] 1 and Day 2 Follow-up phone calls Schedule of Assessments -Part A 
Add CGI-I assessments to Baseline Visit Schedule of Assessments -Part A 
Change footnote â€œmâ€ from screening to baseline  Schedule of Assessments -Part A 
Add remote / home visits details 7.1 Study Assessments 
Add CGI-I assessments (caregiver and clinician) 7.2.2 Baseline 
Add Day 1 and Day 2 Follow-up phone calls 7.2.3 Telephone Follow-up 
Change from screening to baseline visit 7.5.2 CGI-C 
Add Baseline visit 7.5.3 CGI-I 
Plasma drug screen moved to hematology from urinalysis  12.2 Appendix 2 
	
		
 
Confidential Page [ADDRESS_64661] INFORMATION  
SERIOUS ADVERSE EVENT REPORTING:  
In the event of a serious adverse event (SAE), the investigator must notify the sponsor medical 
monitor and the sponsor project manager by e-mail  or fax the Marinus Clinical Study Serious 
Adverse Event Form within 24 hours to Marinus Safety Department at:  
Email: [EMAIL_1144]  
Fax: +[PHONE_1105]  
SPONSOR CONTACTS:  
Sponsor Medical Monitor:  
, MBChB 
Mobile Telephone:   
Email:    
If sponsorâ€™s Medical Monitor cannot be reached in an emergency, the site should contact:  
[CONTACT_59713]-up Medical Monitor: 
, MD  
 Clinical Development 
Mobile Telephone:  Email:  (primary contact [INVESTIGATOR_12183])  
Sponsor Project Managers:  
 
 Clinical Operations 
Office Telephone:
Mobile Telephone:  
Email:  (primary contact [INVESTIGATOR_12183]) 
 
 Clinical Development Operations 
Office Telephone:Mobile Telephone:  (primary contact [INVESTIGATOR_12183]) 
Email:  
	
		
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
 
Confidential Page [ADDRESS_64662] Background and Clinical Information ...........................................................31  
2. STUDY OBJECTIVES AND PURPOSE ..................................................................34  
2.1. Rationale for the Study ...............................................................................................34  
2.2. Study Objectives .........................................................................................................35  
2.2.1.  Primary Objective .......................................................................................................35  
2.2.2.  Secondary Objectives .................................................................................................36  
2.2.3.  Exploratory Objectives ...............................................................................................36  
3. STUDY DESIGN .......................................................................................................36  
3.1. Study Design and Flow Chart .....................................................................................36  
3.2. Duration and Study Completion Definition ................................................................38  
3.3. Sites and Regions ........................................................................................................38  
3.4. Discussion of Study Design ........................................................................................38  
4. STUDY POPULATION .............................................................................................39  
4.1. Inclusion Criteria (Part A) ..........................................................................................39  
4.1.1.  Inclusion Criterion (Part B) ........................................................................................41  
4.2. Exclusion Criteria (Part A) .........................................................................................41  
4.2.1.  Exclusion Criterion (Part B) .......................................................................................43  
4.3. Restrictions .................................................................................................................43  
4.4. Reproductive Potential................................................................................................43  
4.4.1.  Female Contraception .................................................................................................43  
4.4.2.  Male Contraception ....................................................................................................43  
	
		
 
Confidential Page [ADDRESS_64663] .............................................................................47  
6.1.1.  Blinding the Treatment Assignment ...........................................................................47  
6.2. Administration of Investigational Products ................................................................47  
6.2.1.  Allocation of Patients to Treatment ............................................................................47  
6.2.2.  Dosing ........................................................................................................................ .47 
[IP_ADDRESS].  De-escalation Period ...................................................................................................[ADDRESS_64664] A ccountability ......................................................................51  
6.5. Patient Compliance .....................................................................................................52  
7. STUDY PROCEDURES ............................................................................................52  
7.1. Study Assessments......................................................................................................52  
7.2. Study Procedures (Part A:  Treatment Period) ...........................................................52  
7.2.1.  Screening Period .........................................................................................................52  
[IP_ADDRESS].  Screening (Visit 1, Week -4) ......................................................................................52  
7.2.2.  Baseline (Visit 2, Week 0 + 4 days) ...........................................................................53  
7.2.3.  Telephone Follow-up (Day 1, 2 and 3 + 1 days) ........................................................54  
	
		
 
Confidential Page 7 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
7.2.4.  Titration Period (Visit 3, Week 1 Â± 3 days) ................................................................54  
7.2.5.  Titration Period (Phone Follow-ups, Weeks 2, 3, and 4 Â± 3 days) .............................55  
7.2.6.  Maintenance Period (Visits 4 and 5, Weeks 5 and 12 Â± 3 days) ................................55  
7.2.7.  Maintenance Period (Phone Follow-up, Week 9 Â± 3 days) ........................................56  
7.2.8.  Taper and Safety Visits (Visit 5a, Week 16 Â± 3 days) ................................................56  
7.3. Study Procedures (Part B:  OLE Period) ....................................................................[ADDRESS_64665] OLE Visit (Visit 5, Week 12) .............................................................................56  
7.3.2.  OLE Period and Final OLE Visit or Taper Visit (Visits 6, 7, and 8 [or Early 
Discontinuation], Weeks 20, 28, and 36 [or Early Discontinuation] Â± 7 days) ..........57  
7.3.3.  Telephone Follow-up (Weeks 16, 24 and 32 Â± 7 days) ..............................................[ADDRESS_64666] Taper (Visit X,  [ADDRESS_64667] Dose Â± 3 days) ...............58  
7.3.5.  Unscheduled Visits .....................................................................................................58  
7.4. Screening and Diagnosis.............................................................................................58  
7.4.1.  Informed Consent/Assent ...........................................................................................59  
7.4.2.  Drug Screen ................................................................................................................59  
7.4.3.  Demographics and Medical History ...........................................................................59  
7.4.4.  Genetic Testing ...........................................................................................................59  
7.4.5.  Seizure Identification and Diagnostic Review ...........................................................59  
7.5. Efficacy Assessments .................................................................................................59  
7.5.1.  Seizure Type and Frequency ......................................................................................60  
7.5.2.  Caregiver Global Impression of Change (CGI-C - Target Behavior) ........................60  
7.5.3.  Clinical Global Impression â€“ Improvement (CGI-I) ..................................................60  
7.6. Exploratory Efficacy Assessments .............................................................................60  
  
  
7.7. Safety Assessments .....................................................................................................61  
7.7.1.  Adverse Events ...........................................................................................................61  
7.7.2.  Vital Signs ..................................................................................................................6 1 
7.7.3.  Height and Wei ght ......................................................................................................61  
7.7.4.  Physical/Neurological/Developm ental Examinations ................................................61  
7.7.5.  ECG ........................................................................................................................... .63 
7.7.6.  Clinical Laboratory Tests ...........................................................................................63  
7.7.7.  Tanner Staging ............................................................................................................63  
	
		

 
Confidential Page [ADDRESS_64668], Ethics Committee, and Site 
Reporting ....................................................................................................................70  
9. DATA MANAGEMENT AND STAT ISTICAL MET HODS ...................................71  
9.1. Data Collection ...........................................................................................................71  
9.2. Clinical Data Management .........................................................................................71  
9.3. Statistical Analysis Process ........................................................................................71  
9.4. Sample Size Calculation and Power Considerations ..................................................72  
9.5. Analysis Populations ..................................................................................................72  
9.6. Efficacy Analyses .......................................................................................................72  
9.6.1.  Primary Efficacy Endpoint .........................................................................................72  
9.6.2.  Secondary Efficacy Endpoints ....................................................................................72  
[IP_ADDRESS].  Secondary Efficacy:  Seizure control .........................................................................73  
	
		
 
Confidential Page 9 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
[IP_ADDRESS].  Secondary Efficacy:  Other .........................................................................................73  
9.6.3.  Exploratory Efficacy Endpoints .................................................................................73  
9.6.4.  Subgroup Analyses .....................................................................................................74  
9.7. Safety Analyses ..........................................................................................................74  
9.8. Other Analyses............................................................................................................74  
9.9. Pharmacokinetic Analyses ..........................................................................................74  
9.10.  Interim Analysis..........................................................................................................74  
10. SPONSORâ€™S AND INVESTIGATORâ€™S RESPONSIBILITIES  ...............................75  
10.1.  Sponsorâ€™s Responsibilities  ..........................................................................................75  
10.1.1.  Good Clinical Practice (GCP) Compliance ................................................................75  
10.1.2.  Public Posting of Study Information ..........................................................................75  
10.1.3.  Submission of Summary of Clinical Study Report to Competent Authorities 
of Member States Concerned and Ethics Commit tees ...............................................75  
10.1.4.  Study Suspension, Termination, and Completion ......................................................75  
10.2.  Investigatorâ€™s Responsibilities  ....................................................................................76  
10.2.1.  Good Clinical Practice Compliance ............................................................................76  
10.2.2.  Protocol Adherence and Investigator Agreement .......................................................76  
10.2.3.  Documentation and Retention of Records ..................................................................76  
[IP_ADDRESS].  Electronic Case Report Forms (eCRF) .......................................................................76  
[IP_ADDRESS].  Seizure and Medication Diaries ..................................................................................77  
[IP_ADDRESS].  Recording, Access, and Retention of Source Data and Study Documents .................77  
[IP_ADDRESS].  Audit/Inspection .........................................................................................................78  
[IP_ADDRESS].  Financial Disclosure ...................................................................................................78  
10.3.  Ethical Considerations ................................................................................................78  
10.3.1.  Informed Consent/Assent ...........................................................................................[ADDRESS_64669] or Ethics Committee .......................................................79  
10.4.  Privacy and Confidentiality ........................................................................................79  
10.5.  Study Results/Publication Policy ................................................................................80  
11. REFERENCES ...........................................................................................................82  
12. APPENDICES ............................................................................................................84  
12.1.  Appendix 1:  CYP3A4/5/7 Inhibitors and Inducers ...................................................84  
12.2.  Appendix 2:  Clinical Laboratory Tests ......................................................................85  
12.3.  Appendix 3:  Dosing Instructions for Oral Suspension ..............................................86  
	
		
 
Confidential Page [ADDRESS_64670] OF TABLES  
Table 1:  Schedule of Assessments - Part A ..............................................................................24  
Table 2:  Schedule of Assessments - Part B ..............................................................................28  
Table 3:  Oral Suspension Dosinga for Patients Weighing â‰¤ 28 kg (62 lbs)b ............................48  
Table 4:  Oral Suspension Dosinga for Patients Weighing > 28 kg (62 lbs)b .............................[ADDRESS_64671] OF FIGURES  
Figure 1:  Study Design ...............................................................................................................37  
 
	
		
 
Confidential Page [ADDRESS_64672] aspartate aminotransferase 
AUC area under the concentration versus time curve 
Î²-HCG Î²-human chorionic growth hormone 
BP blood pressure 
BUN blood urea nitrogen 
CBD cannabidiol 
CDKL5 cyclin-dependent kinase-like 5 
CGI-C Caregiver Global Impression of Change  
CGI-I Clinical Global Impression â€“ Improvement 
Cmax  maximum plasma concentration 
CNS central nervous system 
CRA clinical research associate 
CRO clinical research organization 
C-SSRS Columbia-Suicide Severity Rating Scale  
CYP cytochrome P450 
DB double-blind 
eCRF electronic case report form 
EC ethics committee 
ECG electrocardiogram 
  
eGFR estimated glomerular filtration rate 
FDA Food and Drug Administration 
FXS fragile X syndrome 
GABA Î³-Aminobutyric acid 
	
		

 
Confidential Page [ADDRESS_64673] 
IS infantile spasms 
ITT intent-to-treat 
IV intravenous 
LAM lymphangioleiomyomatosis 
LAR legally authorized representative 
MedDRA Medical Dictionary for Regulatory Activities 
mTOR mammalian target of rapamycin 
OL open-label 
OLE open-label extension 
PBO placebo 
PCDH19 protocadherin 19 
PI [INVESTIGATOR_59651](s) 
PP Per-Protocol 
Rheb Ras homolog enriched in brain 
RR respi[INVESTIGATOR_59652] 
	
		
 
Confidential Page 13 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Term Definition 
SIF/DRF Seizure Identification and Diagnostic Review Form  
TEAE Treatment-emergent adverse event 
THC tetrahydrocannabinol 
THP tetrahydroprogesterone  
TID three times daily 
tmax  time of maximum concentration 
TSC Tuberous Sclerosis Complex 
ULN upper limit of normal 
US [LOCATION_002] 
VNS Vagus nerve stimulator 
WCBP women of childbearing potential 
 
  
	
		
 
Confidential Page 14 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
STUDY SYNOPSIS  
Protocol number:   1042-TSC-2001 Drug:   ganaxolone (GNX)  
Title of the study :  A Phase 2 open-label 12-week trial of adjunctiv e ganaxolone treatment (Part A) in tuberous 
sclerosis complex -related epi[INVESTIGATOR_59653]-term treatment (Part B). 
Number of patients (total and for each treatment arm):   Approximately 36 tuberous sclerosis complex (TSC) 
patients will be screened to achieve 30 TSC patients enrolled in Part A.  
Investigators:   Multicenter study 
Sites and Regions:   Multicenter study to be conducted at a pproximately 6 sites in the [LOCATION_002] 
Study period (planned): 
March 2020 â€“ January 2022 Clinical phase: 2 
Objectives: 
Primary:  
x To assess preliminary safety and efficacy of GNX as adjunctive therapy for the treatment of primary 
seizure types in patients with genetically- or clinically-confirmed TSC- related epi[INVESTIGATOR_59654] 12-week treatment period.  The primary seizure types (defined later) are identified to be the most 
common, easily identifiable/countable by a parent/caregiver/legally authorized representative (LAR) , and 
most consequential to the patientâ€™s quality of life  
Secondar y: 
x To assess the long-term efficacy of GNX when administered as adjunctive therapy throughout the 
open-label extension (OLE) period (Part B) 
x To assess the long-term safety and tolerability of GNX when administered as adjunctive therapy 
throughout the OLE period (Part B) 
 
  
 
  
 
  
  
  
Rationale:  
Tuberous sclerosis complex  is a multi-system disorder of embryonal cortical developmen t which can impact 
many organs through the overgrowth of hamartomas, benign,  tumorous growths that can occur in the brain and 
other organs.  While the phenotype of TSC can be extremely variable, neurologic manifestations such as epi[INVESTIGATOR_59655] 90% of TSC patients ( Krueger and Northrup, 2013 ).  The condition is caused by [CONTACT_59714]1 gene, located on chromosome 9q34, or the TSC2 gene located on chromosome 
16p13.3.  TSC occurs with a frequency of 1:6,000 and a mutation is found in 85% of patients ( JÃ¼lich and Sahin, 
2014 ).  The gene products hamartin ( TSC1) and tuberin ( TSC2) form a regulatory complex responsible for 
limiting the activity of mammalian targe t of rapamycin (mTOR) complex  1, an important intracellular regulator 
of growth and metabolism that acts via inhibition of the small GTPase Ras homolog enriched in b rain (Rheb) 
(Krueger and Northrup, 2013 ).  Everolimus, an mTOR inhibitor, has been shown to decrease seizures 
(French  et al., 2016 ; Mizuguchi et al., 2019 ). 
Tuberous sclerosis complex  is one of the most common genetic causes of epi[INVESTIGATOR_002], with seizure semiology that 
varies by [CONTACT_59715] ( JÃ¼lich and Sahin, 2014 ).  Infantile spasms (IS) are the most common seizure type 
presenting in infancy and represent the first manifestation of epi[INVESTIGATOR_58824] 50% of patients.  In older children and 
adults, focal impaired awareness seizures (previously known as complex partial seizures) are the most common 
	
		

 
Confidential Page 15 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
(Chu-Shore et al., 2010 ).  Other focal and generalized seizures may  also occur, with over 30% of patients 
developi[INVESTIGATOR_056] -refractory epi[INVESTIGATOR_002] ( JÃ¼lich and Sahin, 2014 ).  While seizures have typi[INVESTIGATOR_59656], epi[INVESTIGATOR_59657] ( JÃ¼lich and Sahin, 2014; van der Poest 
Clement et al., 2020 ). 
Î³-Aminobutyric acid (GABA)ergic signaling may play a meani ngful role in the development and severity of 
TSC-related epi[INVESTIGATOR_002], possibly due to altered expression of endogenous GABA type A (GABA A) receptor 
modula tors ( Di Michele et al., 2003 ).  There is evidence supporting a deficiency of the neuroactive steroid, 3 Î±, 
5Î±-tetrahydroprogesterone (THP), or allopregnanolone, as  a contributor to epi[INVESTIGATOR_59658].  
Allopregnanolone is a positive modulator of the GABA A receptor and has been s hown to have antiepi[INVESTIGATOR_59659].  There is a decrease in allopregnanolone  relative to its functional 
GABA A antagonist, 3 Î²-THP, in patients with TSC- related epi[INVESTIGATOR_59660] ( Di Michele et al., 2003 ).  This reduced ratio could alter ne uronal excitability mediated by [CONTACT_59716] A 
receptors, leading to the development of epi[INVESTIGATOR_59661].  The role of GABA A receptor mediation is also supported by 
[CONTACT_59717], a specific and irreversible inhibitor of GABA -aminotransferase, in seizures due to TSC 
relative to other epi[INVESTIGATOR_31629] ( Di Michele et al., 2003 ).  These findings provide compelling evidence for the 
potential role of neuroactive steroids with anticonvulsant properties, or analogues such as GNX, in the treatment 
of TSC -related epi[INVESTIGATOR_002]. 
Ganaxolone is the 3 Î²-methylated synthetic analog of allopregnanolone, an endogenous positive allosteric 
modulator of central nervous system (CNS) GABA A receptors.  Ganaxolone has potency comparable to 
allopregnanolone in activating s ynaptic and extrasynaptic GABA A receptors at a site distinct from 
benzodiazep ines and barbiturates ( Carter et al., 1997 ).  Ganaxolone has protective activity in diverse rodent 
seizure models  (Bialer et al., 2010; Reddy and Rogwski, 2012 ).  Clinical studies have demonstrated that GNX has 
anticonvulsant activity with an acceptable safety and tolerability profile in the dose range of 900 to 1800 mg 
given orally in adults and children ( Kerrigan et al., 2000 ; Laxer et al., 2000 ; Pi[INVESTIGATOR_59662]., 2007; 
Sperling  et al., 2017 ).  Further, GNX reduces seizures in children with IS and refractory pediatric epi[INVESTIGATOR_002].  In an 
open -label (OL) study, pediatric patients aged 2 to 60 months with refractory seizures and a history of IS were 
treated with GNX doses up to 36 mg/kg for up to 3 months ( Kerrigan et al., 2000 ).  Fifteen pati ents with a history 
of IS completed treatment.  Five of the 15 patients ha d a decrease from baseline in the number of spasms of â‰¥ 
50%, 5  had a decrease of 25% to 50%, and 5 had a decrease of < 25%.  One patient became spasm-free and 1 
non-responder (with a decrease of < 25%) was spasm-free from Weeks 2 to 7.   
A double -blind (DB) study (Study 1042- 0500) of GNX in IS was also conducted.  In this study, patients aged 4 to 
24 months with IS received placebo or GNX doses of up to 54 mg/kg/day for up to 20 days in an incomplete 
crossover design.  A total of 55 of the 57 patients co mpleted treatment, 54 of whom continued GNX treatment in 
Study 1042 -0501, an OLE.  Although the GNX group had numerica lly higher reductions in frequency of spasm 
clusters, no statistica lly significant differences were observed in change from baseline between the treatment 
groups in the frequency of spasm clusters or in any of th e secondary efficacy parameters at the end of the DB 
period (Day 9 Â± 1 day).  
In addition to its anticonvulsant activity, GNX has been shown to reduce anxiety, hyperactivity, and attention in 
children with fragile X syndrome who ha d higher baseline levels of anxiety ( Ligsay et al., 2016 ).  Similar 
behavioral problems occur in individual s with TSC, with rates of approximately 50% for attention deficit 
hyperactivity disorder and autism ( JÃ¼lich and Sahin, 2014 ).  It is hypothesized that GNX treatment will increase 
GABA A-receptor signaling and improve not only seizure cont rol but may also ameliorate the behavioral 
abnormalities in individuals with TSC.  
	
		
 
Confidential Page 16 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Methodology:   This is an OL proof of concept study of adj unctive GNX treatment in patients with a confirmed 
clinical diagnosis of TSC and/or a mutation in either the TSC1 or TSC2  gene.  The trial consists of two parts:  
Part A consists of a 4-week baseline period followed by a 12-week treatment period (4-week titration and 8- week 
maintenance).  For patients not continuing in the OLE period (Part B), a 2 -week taper period followed by a 2-
week safety period would follow.  The main difference betw een Part A and Part B is the length of treatment, less 
frequent assessments, and the ability to alter drug doses (both GNX and other antiepi[INVESTIGATOR_32551] [AED] 
treatments which includes initiating and stoppi[INVESTIGATOR_59663]) based on investigator evaluation of the 
patientâ€™s clinical course during Part B.  Patients with a seizure frequency reduction rate of â‰¥ 35% during the 12 -
week treatment period in Part A compared to baseline  may continue into Part B (â€œOLE eligibleâ€).  If the 
investigator believes there is a medi cal benefit for the patient who does not meet the seizure reduction criterion to 
enter the OLE, they must discuss the patient with the sponsor medical monitor and receive sponsor approval for 
that patient to continue into the OLE.  
Part A  
x 4-week baseline period 
x 4-week titration period 
x 8-week maintenance period  
x 2-week taper period (For patients who do not complete Part A or after completing Part A but do not 
continue into Part B) 
x 2-week safety follow-up visit post taper (For patients who taper off GNX) 
Part B (Op tional for OLE-eligible patients) 
x OLE period (until the Sponsor markets ganaxolone or terminates the study)  
x 2-week taper period (For patients who discontinue  GNX due to early termination or completion) 
x 2-week safety follow-up visit post taper (For patients who taper off GNX) 
  
GNX  = ganaxolone 
During the screening visit, each patientâ€™s baseline  
, will be collected and analyzed for post-study evaluation. 
Patient rescreening is allowed as agreed by [CONTACT_59718] a general concern for 
patient safety or an inability for the patient to become eligible (e.g., GNX allergy, sensitivity or exposure, non-
TSC and/or other ineligible epi[INVESTIGATOR_002], chronic prohibited medical condition or treatment).  Subsequent screening 
should take place at least 30 days from the patientâ€™s last visit, unless otherwise noted.  
Part A includes a 4-week baseline and [ADDRESS_64674] (IP) titration followed by 8 weeks of 
dose maintenance followed by 2 -week taper for those patients not continuing into the Part B OLE period.  After 
meeting all eligibility criteria, approximately 30 patients aged 2 to 65 years (inclusive) with TSC -related epi[INVESTIGATOR_59664] a total of 12 weeks (4 -week titration, 8-week maintenance) in addition to 
their standard anti -seizure medication(s) (ASMs).  Patients will be titrated to 63 mg/kg/day (maximum 
1800  mg/day) over 4 weeks, and then maintained at that dose for another 8 weeks.  Patients who are not able to 
tolerate 63  mg/kg/day (or maximum 1800 mg/day) may be maintained on a lower dose after discussion with the 
sponsor medical monitor.  A minimum dose of 33  mg/kg/day or 900 mg/day is generally required during the 
maintenance period.  
For Part A, dose changes including alternative dosing pa radigm (e.g., lower dose during the daytime and higher 
dose in the evening) should be discussed with the sponsor medical monitor prior to making the change or within 
48 hours of making the change.  Patients  who discontinue GNX should undergo a 2- week taper period, unless 
otherwise medically indicated.  Patients who disconti nue GNX before the completion of the maintenance period 

	
		

 
Confidential Page 17 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
will continue to be followed per protocol and, at a minimum, patients will be encouraged to maintain daily 
seizure diaries until the maintenance period in Part A is completed.  These patients will also return to the site 
2 weeks after the taper for safety follow-up assessments. 
After completin g the initial 16- week period, Part A, patients with a seizure reduction of â‰¥  35% compared to the 
4-week baseline period and who do not ha ve any other contraindications for c ontinued treatment can continue to 
be treated with GNX in the OLE period (Part B).  Patients will continue GNX treatme nt at the dose that they were 
taking at completion of Part A.  Doses of other ASMs may be adjusted (including tapering and initiating 
treatments) during Part  B based on investigator discretion.  Any patient who completes Part A and does not 
continue in Part B, or disconti nues GNX treatment should undergo a 2 -week drug de- escalation (taper) period and 
return to the site 2 weeks later for safety follow -up assessments.   
Patients will be required to complete a daily diary to determine GNXâ€™s effect on seizures.  Days without seizures 
should also be noted.  Additional clinician - and caregiver-administered instruments will be used to assess the 
efficacy of GNX in TSC, and will include:   
x Caregiver Global Impression of Change (CGI-C) - Target Behavior  
x Clinical Global Impression â€“ Improvement (CGI-I) caregiver and CGI-I clinician.  
Inclusion and Exclusion criteria:  Inclusion Criteria (Part A):   
1. Clinical or mutational diagnosis of TSC consistent with Northrup and Krueger, 2013 . 
a. Molecular confirmation of a pathogenic mutation in TSC1  or TSC2 .  A pathogenic mutation is 
defined as a mutation that clearly prevents protein synthesis and/or inactivates the function of the 
TSC1 or TSC2  proteins (e.g., nonsense mutation or frameshift mutations, large genomic deletions) 
or is a missense mutation whose effect on pr otein function has been established by [CONTACT_59719].  The investigator must review the re sults of the genetic analysis and confirm that the 
causal relationship to the epi[INVESTIGATOR_59665].  OR 
b. Clinical diagnosis of definite TS C which includes two major features or one major feature with â‰¥ [ADDRESS_64675] document which of the features (Major or Minor) fulfill the 
clinical diagnostic criteria. 
 
 
Major features Minor features 
1. Hypomelanotic macules ( â‰¥ 3, at least 
5-mm diameter) 
2. Angiofibromas ( â‰¥ 3) or fibrous 
cephalic plaque 
3. Ungual fibromas ( â‰¥ 2) 
4. Shagreen patch 
5. Multiple retinal hamartomas 
6. Cortical dysplasiasa 
7. Subependymal nodules 
8. Subependymal giant cell 
astrocytomas 
9. Cardiac rhabodomyoma 
10. Lymphangioleiomyomatosis (LAM)b 
11. Angiomyolipomas ( â‰¥ 2)b 1. â€œConfettiâ€ skin lesions 
2. Dental enamel pi[INVESTIGATOR_10022] ( â‰¥ 3) 
3. Intraoral fibromas ( â‰¥ 2) 
4. Retinal achromic patch 
5. Multiple renal cysts 
6. Nonrenal hamartomas 
a. Includes tubers and cerebral white matter radial migration lines 
b. A combination of the two major clinical features (LAM and angiomyolipomas) without other features that does 
not meet criteria for a definite diagnosis. 
 
2. Male or female patients aged 2 through 65 years, inclusive. 
3. Patient/parent/caregiver or LAR w illing to give written informed c onsent/assent, after being properly 
informed of the nature and risks of the study and prior to engaging in any study-related procedures.  
Assent for patients over 7 years of age should be obtained, if appropriate. 
	
		
 
Confidential Page [ADDRESS_64676] 8 countable/witnessed primary seizures  during the 4-week baseline period with at least 
[ADDRESS_64677] 3 of the 4 weeks of baseline.  The primary seizure types are 
defined as the following:  focal motor seizures wit hout impairment of consciousness or awareness, focal 
seizures with impairment of consciousness or awar eness, focal seizures evolving to bilateral, 
tonic-clonic convulsive seizures, and ge neralized motor seizures including tonic- clonic, bilateral tonic, 
bilateral clonic, or atonic/drop seizures.  Focal aware non- motor and generalized seizures without motor 
features, infantile or epi[INVESTIGATOR_59666] , and myoclonic seizures do not count as the primary seizure types. 
6. Patient must be approved to partic ipate by [CONTACT_3552] (e.g., Epi[INVESTIGATOR_59667]) after 
review of medical history, genetic testing, and patientsâ€™ seizure types.  
7. Patients s hould be on a stable regimen of ASMs at therapeutic doses for â‰¥ 1 month prior to the screening 
visit, without a foreseeable change in dosing for the duration of Part A.  Vagus nerve stimulator (VNS), 
ketogenic diet, and modified Atkins diet should be unchanged for 3 months prior to screening and will 
not count towards the number of ASMs. 
8. Patients with surgically implanted VNS will be al lowed to enter the study provided that all of the 
following conditions are met: 
a. The VNS has been in place for â‰¥  [ADDRESS_64678] for th e duration of baseline and Part A. 
9. Parent/caregiver is able and willing to maintain an  accurate and complete daily seizure diary for the 
duration of the study. 
10. Able and willing to take IP (suspension) with food 3 times daily.  (GNX must be administered with 
food.) 
11. Sexually active female of childbearing poten tial must be using a medically acceptable method of birth 
control and have a nega tive quantitative serum Î²-human chorionic growth hormone ( Î²-HCG) test 
collected at the initial screening visit.  Childb earing potential is defined as a female who is biologica lly 
capable of becoming pregnant.  A medically acceptabl e method of birth control includes intrauterine 
devices in place for at least 3 months prior to the screening visit, surgical sterilization, or adequate 
barrier methods (e.g., diaphragm or condom and foam).  An oral contraceptive alone is not considered 
adequate for the purpose of this study.  Use of oral  contraceptives in combination with another method 
(e.g., a spermicidal cream) is acceptable.  In patien ts who are not sexually active, abstinence is an 
acceptable form of birth control.   
Inclusion Criteria (Part B)  
1. Patients have experienced â‰¥ 35% reduction in primary seizure fre quency during the Part A treatment 
period compared to the 4-week Baseline Period. 
Exclusion Criteria (Part A):   
1. Previous exposure to GNX. 
2. Pregnant or breastfeeding. 
3. Concurrent use of strong inducers or inhibitors of cytochrome P450 (CYP)3A4/5/7.  Any strong 
inhibitor or inducer of CYP3A4/5/[ADDRESS_64679] positive for tetrahydrocannabinol  (THC) or non-approved cannabidiol (CBD) via 
plasma drug screen.  
6. Chronic use of oral steroid medications, ketoconazole (except for topi[INVESTIGATOR_29899]), St. Johnâ€™s Wort, 
or other IPs is not permitted. 
7. Adrenocorticotropic hormone (ACTH), prednisone, or other systemically administered (non- inhaled) 
steroids must be discontinued > 28 days prior to screening.  Concomitant topi[INVESTIGATOR_2855], inhaled or intranasal 
steroids are allowed and do not warrant exclusion from the study.  
	
		
 
Confidential Page 19 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
8. Changes in any chronic medications within the month (e.g., 30 days) prior to the screening visit.  All 
concomitant medications must have been  at a stable in dose for at least 1- month prior to the screening 
visit unless otherwise noted.   
9. Patient is being considered for epi[INVESTIGATOR_59668] 
[ADDRESS_64680] any disease or condition (medical or surgical; other than TSC) at the screening visit that might 
compromise the hematologic, cardiovascular, pulmonary, rena l, gastrointestinal, or hepatic systems; or 
other conditions that might interfere with the absorption, distribution, metabolism, or excretion of the IP, 
or would place the patient at increased risk.  This may include any illness in the past [ADDRESS_64681] seizure frequency.  
12. An aspartate aminotransferase (AST/serum glutamic oxaloacetic transaminase [SGOT]) or alanine 
aminotransferase (ALT/serum glutamic pyruvic tran saminase [SGPT]) > 3 Ã— the upper limit of normal 
(ULN) at screening or baseline visits  and confirmed by a repeat test.   
13. Total bilirubin levels > 1.5 Ã— ULN at screening or baseline visit and confirmed by a repeat test.  In cases 
of documented, stable medical condition (i.e., Gilbertâ€™s Syndrome) resultin g in levels of total bilirubin 
> ULN, the medical monitor can determin e if a protocol exception can be made. 
14. Patients with significant renal insufficiency, estimated glomerular filtration rate (eGFR) < 30 mL/min 
(calculated using the Cockcroft-Gault formul a or Pediatric GFR calculator or Bedside Schwartz), will be 
excluded from study entry or will be discontinued if the criterion is met post baseline. 
15. Have been exposed to any other investigational dr ug within 30 days or fewer than 5 half-lives 
(whichever is shorter) prior to the screening visit.   
16. Unwillingness to withhold grapefruit, Seville oranges,  star fruit, or grapefruit containing products from 
diet [ADDRESS_64682] had an active suicidal plan/intent o r active suicidal thoughts in the past [ADDRESS_64683] 3 years.   
18. Known sensitivity or allergy to any component in  the IP(s), progesterone or other related steroid 
compounds. 
Exclusion Criteria (Part B):  
1. Patient developed a medical condition that would make it unsafe for patients to received GNX as 
determined by [CONTACT_093].  
Number of patients:   Approximately [ADDRESS_64684], dose, and mode of administration:  Ganaxolone is to be administered in increments 
of 15  mg/kg/day up to 63 mg/kg/day (maximum 1800 mg/day) given as an oral suspension with food.  Patients 
weighing â‰¤ 28 kg will be dosed on an mg/kg basis.  Patients weighing > 28 kg will be dosed on a fixed regimen 
in increments of 450  mg/day up to 1800 mg/day.  Ganaxolone is to be administered during the 4- week titration 
period as follows:  
Oral Suspension Dosinga for Patients Weighing â‰¤ 28 kg (62 lbs)b 
Dose mg/kg Total mg/kg/day Days 
6 TID 18 1-7 
11 TID 33 8-14 
16 TID 48 15-21 
21 TID 63 22-28 
Oral Suspension Dosinga for Patients Weighing > 28 kg (62 lbs)c 
Dose mg mL per Dose Total mg/day Days 
150 TID 3 450 1-7 
	
		
 
Confidential Page 20 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
300 TID 6 900 8-14 
450 TID 9 1350 15-21 
600 TID 12 1800 22-28 
TID = 3 times daily. 
a. To be administered in 3 divide d doses following a meal or snack. 
b. Patients weighing â‰¤ 28 kg will be dosed according to the patientâ€™s weight in kilograms.  
c. Patients weighing > 28 kg will be dosed on a fixed regimen in increments of 450 mg/day up to 
1800 mg/day.  
Any patient not tolerating the next dose step can be maintain ed at the lower dose step for additional days before 
advancing to the next dose.  If the next dose is still not tolerated, the patient can drop back to the next lower dose 
step.  A minimum dose o f 33 mg/kg/day or 900 mg/day is generally required following the escalation period, 
during the maintenance period.  
Dose changes including alternative dosing paradigms (e.g., lower dose during the daytime and higher dose in the 
evening) should be discussed  with the sponsor medical monitor prior to making the change or within [ADDRESS_64685] the sponsor medical monitor 
to discuss continued IP dosing.  Patients who discontinue GNX treatment before the completion of the 
maintenance period in Part A will continue to be fo llowed per protocol and, at a minimum, patients  will be 
encouraged to maintain daily seizure diary entries until Part A is completed. 
During Part B, patients who meet all of the inclusion cr iteria and none of the exclusion criteria will initiate 
treatment in Part B with GNX at the same dose they were on at  the completion of Part A.  During Part B, doses of 
GNX may be adjusted to a maximum of 600  mg three times daily (TID) for patients weighing > 28 kg and a 
maximum dose of 21/mg/kg TID for patients weighing â‰¤  28 kg.  
Duration of treatment:   After 4 weeks of baseline seizure charting, patients will initiate a 4-week GNX titration 
period followed by [CONTACT_1629] 8 -week GNX maintenance period (Part A).  Pa tients completing Part A and deemed 
eligible for Part B will continue taking GNX. Patients will have the option to continue longer- term treatment on 
ganaxolone until commercially available or  the study is terminated by [CONTACT_1034].  Anyone discontinuing GNX 
will undergo a 2 -week taper and a 2-week follow-up safety visit.   
The planned study duration is approximately 64 weeks for patients who stay on the study through Part B.  
Criteria for Evaluation:   
Seizures:   All seizure types and number of seizures will be recorded daily in a diary.  Days in which no seizures 
occur will also be noted.  Subsets of seizure types will be defined below.  
Primary Efficacy Endpoint:  The primary efficacy endpoint is the percent change in 28- day primary seizure 
frequency through the end of the 12 -week treatment period (4-week titration and 8- week maintenance) relative to 
the 4 -week baseline.  The primary seizure types are define d as the following:  focal motor seizures without 
impairment of consciousness or awareness, focal seizures with impairment of consciousness or awareness, focal 
seizures evolving to bilateral, tonic -clonic seizures, and generalized motor seizures including tonic-clonic, 
bilateral tonic, bilateral clonic, and at onic/drop seizures.  Focal aware non- motor and generalized seizures without 
motor features, infantile or epi[INVESTIGATOR_59666], and myocl onic seizures are not considered primary seizure types.  
Post-baseline 28-day seizure frequency will be calcu lated as the total number of seizures in the 12- week treatment 
period (4 -week titration and 8- week maintenance periods) divided by [CONTACT_59720], multiplied by 28.  Baseline 28 -day seizure frequency will be calculat ed as the total 
number of seizures in the baseline peri od divided by [CONTACT_59721] 28.  Descriptive statistics w ill be used to summarize ch anges in seizure frequency.  
No inferen tial statistical testing will be performed.  
Secondary Efficacy Endpoints (Seizure control):  Derived seizure secondary eff icacy endpoints will be based 
on data through the end of the 12-week treatment period relative to the 4-week prospective baseline period.  
	
		
 
Confidential Page 21 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Percentage of patients experiencing a â‰¥ 50% reduction in 28 -day primary seizure frequency 
through the end of the 12-week treatment period compared to the 4-week Baseline Period. 
Secondary Efficacy Endpoints (Other):  
x CGI-I, parent/caregiver and clinician 
x CGI-C - Target Behavior 
 
 
  
  
 
 
  
 
  
  
 
  
 
  
  
 
  
Pharmacokinetic Assessments: 
The pharmacokinetic (PK) population will include all patien ts who have received at least [ADDRESS_64686] dose du ring Part A and Part B.  Pharmacokinetic analyses 
will be limited to listing of concentrations because sufficient concentration-time data will not be available for 
noncompartmental  analyses such as maximum plasma concentration (C max), area under the concentration versus 
time curve (AUC), or time of maximum concentration (t max).  Pharmacokinetic data from this study may be used 
for a Population PK analyses to be conducted separately from this study and reported separately.  Further details 
will be prov ided in the Statistical Analysis Plan. 
Safety and Tolerability Assessments: 
Safety and tolerability will be assessed by [CONTACT_49126] (blood pressure [BP], heart rate [HR], 
respi[INVESTIGATOR_697] [RR], body temperature, electrocardiograms (ECGs), clinical laboratory tests (hematology, 
chemistry and urinalysis), physical, neurological, and developmental examinations, Columbia -Suicide Severity 
Rating Scale (C -SSRS) if appropriate and freque ncy, type, and severity of adverse events (AEs) during Part A 
and Part  B.  Height and weight will also be measured.  
Statistical Methods:  
The intent -to-treat (ITT) population comprises all patients who received at least one dose of IP.  The ITT 
population will be the primary population fo r efficacy analyses.  The Per- Protocol (PP) population includes all 
ITT patients without major protocol violations (defined pr ior to database lock).  Safety will be reported in all 
patients.  
Since this is an OL proof of concept study, no inferent ial statistical testing will be  conducted, and all efficacy 
outcomes will be descriptive.  
	
		

 
Confidential Page 22 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Primary Endpoint:  Definition and Analysis: 
The primary efficacy endpoint (change in seizu re frequency) is the percent change in 28 -day seizure frequency 
through the end of the  12-week treatment period (4-week titration and 8-week maintenance) relative to the 
baseline, based on the primary seizure types.  The primary seizure types are defined as the following:  focal motor 
seizures without impairment of consciousness or awareness,  focal seizures with impairment of consciousness or 
awareness, focal seizures evolving to bilateral, tonic -clonic convulsive seizures, a nd generalized motor seizures 
including tonic -clonic, bilateral tonic, bilater al clonic, or atonic/drop seizures.  Focal aware non-motor and 
generalized seizures without motor features, infantile or epi[INVESTIGATOR_59666], and myoclonic seizures do not count as 
the primary seizure types.  
Post-baseline 28-day seizure frequency will be calculate d as the total number of seizures in the 12- week treatment 
periods (4 -week titration plus 8-week maintenance period) during Part A divided by [CONTACT_59722], multiplied by 28.  Baseline [ADDRESS_64687] -baseline, and arithmetic and percen t changes from baseline in 28- day seizure frequency will be 
summarized using descriptive statistics.  
Since this is an OL proof of concept study, all efficacy analyses will be based on descriptive stati stics. 
Sample Size:  
Since this is an OL proof of concept study, sample size was not determined by [CONTACT_59723].  
Secondary and Exploratory Endpoints - Descriptive Evaluation: 
Seizure control:  
x Percentage of patients experiencing a â‰¥ 50% reduction in 28 -day primary seizure frequency 
through the end of the 12-week treatment period compared to the 4-week Baseline Period.  
Other:  
x CGI-I, parent/caregiver and clinician.  
x CGI-C - Target Behavior. 
Exploratory Endpoints - Descriptive Evaluation:  
All secondary and  
  
 
 
  
  
   
  
 
 
  
 
  
  
 
  
 
 
  

	
		

 
Confidential Page 23 of 88 IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
  
 
  
Safety Analysis:   Safety will be reported for all patients.  The results in Part A and Part B will be summarized 
separately and then the combined results in Part A and Part B will be summarized together.  Adverse events will 
be tabulated by [CONTACT_59724], system organ class, and Preferred Term using the Medical Dictionary for Regulatory 
Activities (MedDRA) coding system.  Incidence and percentage of AEs w ill be presented.  Additional tables, 
with AEs classified by [CONTACT_59725].  
Subset listings will be produced for AEs that cause wit hdrawal and for serious adverse events (SAEs).  Clinical 
laboratory tests (hematology, chemistry and urinalysis), vital signs (temperature, BP, pulse rate), weight, and ECGs will be summarized using descriptive statisti cs including changes from ba seline.  Change in C
-SSRS scores 
where applicable will  be determined.  Physical, neurological and developmental examinations will be 
summarized using number and percentage of patients with abnormalities . 
Pharmacokinetic Analysis:  A population PK approach addressing the relationship between GNX PK 
parameters  and individual characteristics will be implemen ted during the study.  One blood sample will be 
obtained at the following visits for PK analyses:  
x During Part A: 
- Visit 4 (Week 5):  between [ADDRESS_64688] IP dosing  
- Visit 5 (Week 12):  between [ADDRESS_64689] IP dosing 
x During Part B:  There is no specified time to draw the PK sample and can be drawn when convenient 
during the study visits. 
Exact time of sample withdrawal and drug intake will  be recorded in the electronic case report form (eCRF) .   
 and Concomitant AED levels :  Blood s amples will be drawn at screening visit, 
  Conc omitant AED levels will not be mandatory but 
will be conducted per sitesâ€™ standard of care.  If AED levels are availabl e, the results, date and time of last AED 
dose and date and time of AED PK samp le will be recorded in the eCRF .   and concomitant AED 
levels will be analyzed according to the SAP.  
Interim Analysis:  No formal interim analysis is planned.   
	
		

IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
Confidential Page 24 of 88 Table 1: Schedule of Assessments - Part A 
   Part A 
 Screen/Baseline    Titration and Maintenance 
WEEK -4 
(Screening 
Visit â€“  
Start of 
Baseline) 0 
(Baseline 
Treatment 
Visit)  
 
 
 
Day 
1  
 
 
 
Day 
2 Day 
3 1 2, 3, 
4 5 9 12 16 
Taper/Safety Visitsp 
Visit Windows  + 4 days   
Â± 1 day Â± 3 
days Â± 3 
days Â± 3 
days Â± 3 days Â± 3 
days Â± 3 days 
VISIT Visit 1a Visit 2o Phone 
Follow-
up Phone 
Follow-
up Phone 
Follow-
up Visit 
3 Phone 
Follow-
up Visit 
4 Phone 
Follow-up Visit 
5 Visit 5a 
Informed Consentb X           
Demographics & 
Medical History X Xs          
Inclusion/Exclusion 
Criteria X X          
Genetic testing Xc Xr          
Seizure Identification 
and Diagnostic 
Review Form 
(Epi[INVESTIGATOR_59669]) X X          
Vital Signs (BP, HR, 
RR, and body 
temperature) X X    X  X  X X 
Height / weight Xd Xe    Xe  Xe  Xe  
Physical/Neurological/ 
Developmental Examt X X    X  X  X  
ECG  X    X  X  X  
Clinical Laboratory 
Testsf X X    X  X  X  
Urinalysis Xg Xg    X  X  X  
Drug Screenh X X        X  
Pregnancy Test 
(WCBP)i X X      X  X  
	
		
IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
Confidential Page 25 of 88 Table 1: Schedule of Assessments - Part A 
   Part A 
 Screen/Baseline    Titration and Maintenance 
WEEK -4 
(Screening 
Visit â€“  
Start of 
Baseline) 0 
(Baseline 
Treatment 
Visit)  
 
 
 
Day 
1  
 
 
 
Day 
2 Day 
3 1 2, 3, 
4 5 9 12 16 
Taper/Safety Visitsp 
Visit Windows  + 4 days   
Â± 1 day Â± 3 
days Â± 3 
days Â± 3 
days Â± 3 days Â± 3 
days Â± [ADDRESS_64690] of Care
k X X    X  X  X  
            
Adverse Event X X X X X X X X X X X 
Seizure and 
Medication Diary 
Reviewl Xl X X X X X X X X X X 
            
CGI-C - Target 
Behavior  Xm      X  X  
CGI-I (caregiver)  X      X  X  
CGI-I (clinician)  X      X  X  
C-SSRS (baseline 
form)q  X          
C-SSRS (since previous 
visit)q        X  X X 
Dispense GNXn  X      X  X  
AED = antiepi[INVESTIGATOR_32551], BP = blood pressure, CBD = cannabidiol, CGI-C = Caregiver Global Impression of Change, CGI-I = Clinic al Global Impression â€“ Improvement, 
C-SSRS = Columbia-Suicide Severity Rating Scale, D/C = discontinuation, ECG = electrocardiogram, , GNX  = ganaxolone, HR = heart rate, 
IP = investigational product, LAR = legally authorized representative, PK = pharmacokinetic, RR = respi[INVESTIGATOR_697], THC = tetrahy drocannabinol, WCBP = women of 
childbearing potential. 
	
		

IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
Confidential Page 26 of 88 Table 1: Schedule of Assessments - Part A 
   Part A 
 Screen/Baseline    Titration and Maintenance 
WEEK -4 
(Screening 
Visit â€“  
Start of 
Baseline) 0 
(Baseline 
Treatment 
Visit)  
 
 
 
Day 
1  
 
 
 
Day 
2 Day 
3 1 2, 3, 
4 5 9 12 16 
Taper/Safety Visitsp 
Visit Windows  + 4 days   
Â± 1 day Â± 3 
days Â± 3 
days Â± 3 
days Â± 3 days Â± 3 
days Â± 3 days 
VISIT Visit 1a Visit 2o Phone 
Follow-
up Phone 
Follow-
up Phone 
Follow-
up Visit 
3 Phone 
Follow-
up Visit 
4 Phone 
Follow-up Visit 
5 Visit 5a 
a. Patient rescreening is allowed as agreed by [CONTACT_59718] a general concern for patient s afety or an inability for the patient to become 
eligible (e.g., GNX allergy, sensitivity or exposure, non- TSC and/or other ineligible epi[INVESTIGATOR_002], chronic prohibited medical condition or treatment).  Subsequent screening 
should take place at least 30 days from the patientâ€™s last visit.  
b. Written informed consent/assent must be obtained from patient, parent or LAR before any study assessments are performed.  Pedi atric assent should be obtained, if 
appropriate. 
c. Previous genetic testing results will be accepted and reviewed to assess if a pathogenic TSC1  or TSC2  variant is present.  If genetic testing has not previously been 
performed, then a biological sample will be obtained to complete genetic testing at the sponsorâ€™s designated lab.  Note:  TSC  diagnosis does not require pathogenic TSC1  
or TSC2  mutations if the clinical criteria are met.   
d. Height and weight will be measured.  Length will be measured if height cannot be obtained. 
e. Only weight will be measured.  At each visit, dosing will be reviewed and adjusted as needed based on a patientâ€™ s current weight.  
f. Chemistry and Hematology.   
g. An attempt should be made to collect a urine sample for a urinalysis at screening; otherwise, the urine sample can be collecte d at baseline for the urinalysis if possible. 
h. A drug screen (plasma) will be performed to test for THC and CBD at screening.  If the screening drug test is positive, the pa tient can be retested, via plasma, after two 
weeks.  A positive drug test during the treatment period will result in early termination.  
i. Serum pregnancy test is required for all girls/women of childbearing potential.   
j. Population PK will be conducted at these visits (Visit 4:  between 1-[ADDRESS_64691] IP dosing, Visit 5:  between 4-[ADDRESS_64692] IP dosing).   
k. Concomitant AEDs or their dose must be stable for 1 month prior to screening and cannot be changed at any time prior to Visit 4, but may be adjusted during Part B. 
l. Caregiver given seizure and medication diary and instructions for use. 
m. During the baseline visit, the investigator and parent/caregiver/LAR will decide on a domain and identify the specific behavio r that the patient exhibits that denotes the 
domain.  This behavior will be used at subsequent visits to assess change after the initiation of IP. 
n. Patients who discontinue IP early will be encouraged to continue with all procedures and scheduled visits. 
o. The 4 weeks between Screening Visit and Baseline Treatment Visit can be no less than 28 days and no more than 32 days. 
p. Only for patients who do not continue into Part B.  This will occur after 2 weeks of taper and 2 weeks after completion of tre atment. 
q. Only for patients â‰¥ [ADDRESS_64693] performed at the sponsorâ€™s designated lab.  
	
		
IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
Confidential Page 27 of 88 Table 1: Schedule of Assessments - Part A 
   Part A 
 Screen/Baseline    Titration and Maintenance 
WEEK -4 
(Screening 
Visit â€“  
Start of 
Baseline) 0 
(Baseline 
Treatment 
Visit)  
 
 
 
Day 
1  
 
 
 
Day 
2 Day 
3 1 2, 3, 
4 5 9 12 16 
Taper/Safety Visitsp 
Visit Windows  + 4 days   
Â± 1 day Â± 3 
days Â± 3 
days Â± 3 
days Â± 3 days Â± 3 
days Â± 3 days 
VISIT Visit 1a Visit 2o Phone 
Follow-
up Phone 
Follow-
up Phone 
Follow-
up Visit 
3 Phone 
Follow-
up Visit 
4 Phone 
Follow-up Visit 
5 Visit 5a 
s. Review of medical history only. 
t. Developmental examination is limited to pediatric patients 2 to 17 years of age, inclusive. 
  
	
		
IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
Confidential Page 28 of 88 Table 2: Schedule of Assessments - Part B 
Part B 
 Final 
Part A 
Visit/ 
First 
Part B 
Visit Open-Label Extension 
(Visits will be every 8 weeks with a telephone follow-up in-between) Final OLE Visit or 
Taper Visit Safety  
Follow- up 
Post-taper 
WEEK 12 16 20 24 28 32 36 or early D/C [ADDRESS_64694] 
dose 
Visit Windows  Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 3 days 
VISIT Visit 5 Phone 
follow-up Visit 6 Phone 
follow-up Visit 7 Phone 
follow-up Visit 8 (Week 36)g 
or Visit X (early 
D/C) Visit X 
Confirm patient is â€œOLE 
eligibleâ€ ( â‰¥ 35% reduction in 
seizure frequency) X        
Vital signs (BP, HR, RR, 
and body temperature)  X  X  X  X X 
Weighta X  X  X  X  
Physical/Neurological/ 
Developmental Exam X  X  X  X X 
ECG X    X  Xd  
Clinical Laboratory Testsb X  X  X  X X 
Urinalysis X    X  X X 
Drug Screen  X    X    
Pregnancy Test (WCBP)c X  X  X  X X 
Tanner Staging       Xd  
IP PKe X  X  X  X X 
Concomitant AED Review 
and levels if per standard of 
care X  X  X  X X 
	
		
IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
Confidential Page 29 of 88 Table 2: Schedule of Assessments - Part B 
Part B 
 Final 
Part A 
Visit/ 
First 
Part B 
Visit Open-Label Extension 
(Visits will be every 8 weeks with a telephone follow-up in-between) Final OLE Visit or 
Taper Visit Safety  
Follow- up 
Post-taper 
WEEK 12 16 20 24 28 32 36 or early D/C [ADDRESS_64695] 
dose 
Visit Windows  Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 3 days 
VISIT Visit 5 Phone 
follow-up Visit 6 Phone 
follow-up Visit 7 Phone 
follow-up Visit 8 (Week 36)g 
or Visit X (early 
D/C) Visit X 
         
Adverse Event X X X X X X X X 
Seizure and Medication 
Diary Review X X X X X X X X 
         
CGI-C - Target Behavior X      X  
CGI-I (caregiver) X      X  
CGI-I (clinician) X      X  
C-SSRS (since last visit 
form)f X  X  X  X  
Dispense GNX X  X  X  X  
AED = antiepi[INVESTIGATOR_32551], BP = blood pressure, CGI-C = Caregiver Global Impression of Change, CGI-I = Clinical Global Impressio n â€“ Improvement, 
C-SSRS = Columbia-Suicide Severity Rating Scale, D/C = discontinua tion, ECG = electrocardiogram, , GNX  = ganaxolone, 
HR = heart rate, IP = investigational product, OLE = open-label ex tension, PK = pharmacokinetic, RR = respi[INVESTIGATOR_697], WCBP = wo men of childbearing 
potential.  
a. Weight will be measured at every visit, except the safety follow-up visit. 
b. Chemistry and Hematology. 
c. Serum pregnancy test is required for al l girls/women of childbearing potential. 
d. Conduct at Week 36/Visit [ADDRESS_64696] open-label  extension visit if prior to Week 36/Visit 8. 
e. PK samples can be drawn when convenient during the study visits. 
	
		

IND 044,020  Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
Confidential Page 30 of 88 Table 2: Schedule of Assessments - Part B 
Part B 
 Final 
Part A 
Visit/ 
First 
Part B 
Visit Open-Label Extension 
(Visits will be every 8 weeks with a telephone follow-up in-between) Final OLE Visit or 
Taper Visit Safety  
Follow- up 
Post-taper 
WEEK 12 16 20 24 28 32 36 or early D/C [ADDRESS_64697] 
dose 
Visit Windows  Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 7 days Â± 3 days 
VISIT Visit 5 Phone 
follow-up Visit 6 Phone 
follow-up Visit 7 Phone 
follow-up Visit 8 (Week 36)g 
or Visit X (early 
D/C) Visit X 
f. Only for patients â‰¥ 7 years old if appropriate.  Otherwise clinical judgment will be used. 
g.    Cons istent with V8 (Week 36) or Visit X, patients can be seen at Investigatorâ€™s discretion for unscheduled visits.  
 
	
		
 
Confidential  Page 31 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
1. BACKGROUND INFORMATION 
1.1. Indication and Current Treatment Options 
Tuberous Sclerosis Complex (TSC) is a multi-system disorder of embryonal cortical 
development which can impact many organs through the overgrowth of hamartomas, benign, 
tumorous growths that can occur in the brain and other organs.  While the phenotype of TSC can be extremely variable, neurologic manifestations such as epi[INVESTIGATOR_59670] 90% of TSC patients. ( Krueger and Northrup, 2013 ).  The condition is caused by [CONTACT_59726]1 gene, located on chromosome 9q34, or the TSC2 gene located on chromosome 
16p13.3.  Tuberous Sclerosis Complex occurs with a frequency of 1:6,000 and a mutation is found in 85% of patients ( JÃ¼lich and Sahin, 2014 ).  The gene products hamartin ( TSC1) and 
tuberin ( TSC2 ) form a regulatory complex responsible for limiting the activity of mammalian 
target of rapamycin (mTOR) complex 1, an important intracellular regulator of growth and metabolism that acts via inhibition of the small GTPase Ras homolog enriched in brain (Rheb) 
(Krueger and Northrup, 2013 ).  Everolimus, an mTOR inhibitor, has been shown to decrease 
seizures ( French et al., 2016 ; Mizuguchi et al., 2019 ). 
Tuberous Sclerosis Complex is one of the most common genetic causes of epi[INVESTIGATOR_002], with seizure 
semiology that varies by [CONTACT_59715] ( JÃ¼lich and Sahin, 2014 ).  Infantile spasms (IS) are the 
most common seizure type presenting in infancy and represent the first manifestation of epi[INVESTIGATOR_59671] 50% of patients.  In older children and adults, focal impaired awareness seizures (previously 
known as complex partial seizures) are the most common ( Chu-Shore  et al., 2010).  Other focal 
and generalized seizures may also occur, with over 30% of patients developi[INVESTIGATOR_056]-refractory epi[INVESTIGATOR_002] ( JÃ¼lich and Sahin, 2014 ).  While seizures have typi[INVESTIGATOR_59672], epi[INVESTIGATOR_59673] (JÃ¼lich and Sahin, 2014 ; van der Poest Clement et al., 2020 ). 
Treatment options depend on the type and severity of seizures.  Vigabatrin is widely accepted as 
the first-line treatment for IS associated with TSC.  For other seizure types, conventional 
antiepi[INVESTIGATOR_006] (AEDs) such as valproic acid, topi[INVESTIGATOR_052], and oxcarbazepi[INVESTIGATOR_59674]-line AEDs in TSC although there are no data supporting TSC-specific efficacy.  
Additionally, there are disease-modifying drugs that target inhibition of the mTOR pathway such as everolimus.  A randomized clinical trial demonstrated efficacy of everolimus on seizure frequency reduction and is Food and Drug Administration (FDA)-approved for treatment of 
focal-onset seizures associated with TSC.  More recently, cannabidiol (CBD) (EPI[INVESTIGATOR_59675]
Â®) 
demonstrated seizure reduction efficacy in a randomized controlled trial. 
1.2. Product Background and Clinical Information 
Ganaxolone (GNX) is the 3 Î²-methylated synthetic analogue of the neuroactive steroid 
allopregnanolone, but it is designed to not activate nuclear (classical) progesterone receptors.  
Ganaxolone differs from other Î³-Aminobutyric acid (GABA) agents by [CONTACT_59727]-synaptic GABA type A (GABA A) receptors and at binding sites distinct from 
benzodiazepi[INVESTIGATOR_1651].  Whereas benzodiazepi[INVESTIGATOR_59676], GNX does not because it selectively binds to GABA
A receptors containing the Î± and Î´  subunits.  By [CONTACT_14377] 
	
		
 
Confidential  Page [ADDRESS_64698] fully-kindled Stage-5 seizures induced by [CONTACT_59728].  Seizure threshold, as determined by [CONTACT_59729] (IV)-infused pentylenetetrazol required to induce clonus, was significantly elevated by [CONTACT_105]-toxic doses of GNX in the mouse.  These results indicate that GNX blocks seizure propagation and elevates seizure threshold (Carter et al., 1997 ; Kaminski et al., 2004 ; Reddy et al., 2004 ). 
The completed GNX clinical program comprises 20 Phase 1 studies in healthy subjects and 
20 Phase 2 studies in adults with epi[INVESTIGATOR_002], children with seizure disorders, children with 
fragile X syndrome (FXS), adults with post-traumatic stress disorder and adults with migraine.  In these studies, the efficacy, safety, tolerab ility, pharmacokinetics (PK), and PD of GNX were 
evaluated with an oral dosing duration ranging from 1 day up to more than 2 years, using doses from 50 to 2000 mg/day.  Additionally, IV bolus  doses ranging from 10 to 30 mg over durations 
of 2 minutes to 1 hour or a bolus dose of 6 mg over 5 minutes followed with a continuous 
infusion of 20 mg per hour for 4 hours were evaluated in healthy subjects ( Ganaxolone, 2019 ). 
As of [ADDRESS_64699] 1 dose of GNX 
across the 40 completed studies.  This includes 319 patients in Phase 1 and 1238 patients in Phase 2/3 studies. 
In 20 completed Phase 1 studies, 319 healthy subjects received GNX oral doses of 50 to 
2000 mg/day for periods of up to 2 weeks, or IV bolus doses ranging from 10 to 30 mg over durations of 2 minutes to 1 hour or a bolus dose of 6 mg over 5 minutes followed with a 
continuous infusion of 20 mg per hour for 4 hours. 
In the 20 completed Phase 2/[ADDRESS_64700]-traumatic stress disorder, and adult patients with migraine. 
The ongoing GNX clinical program consists of 6 Phase 2/3 studies evaluating GNX in women 
with postpartum depresssion, children with refractory epi[INVESTIGATOR_59677] 19 
(PCDH19) epi[INVESTIGATOR_002], cyclin dependent kinase-like 5 (CDKL5) deficiency disorder and other rare genetic epi[INVESTIGATOR_31629], and in adolescents and adults with SE.  Additionally, two Phase 1 studies designed to evaluate metabolites of GNX in healthy lactating females and healthy males are ongoing. 
In addition to the company-sponsored studies, 18 patients were treated with GNX in completed 
studies not sponsored by [CONTACT_59730].  These included 16 patients who received oral GNX doses 
from 400 to 1200 mg/day in a smoking cessation study.  In addition,  
	
		

 
Confidential  Page 33 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
 
  
 
The overall frequency of treatment-emergent adverse events (TEAE) in company-sponsored 
placebo (PBO)-controlled studies was 61.7% (613/993 patients) in patients who received GNX 
and 51.8% (330/637 patients) in patients who received PBO.  The most frequently reported 
TEAEs in GNX-treated patients were somnolence, dizziness, fatigue, and headache.  All of these events, except for headache, occurred more frequently in GNX-treated patients than PBO-treated patients.  Central nervous system (CNS)-related events appeared to be dose-related, with the majority of these events occurring at doses â‰¥ [ADDRESS_64701] been noted for 
electrocardiogram (ECG) interva ls, vital signs, physical or neurologic examinations, or mean 
changes from baseline in clinical laboratory results.  Overall, there have been a few clinically significant individual changes from baseline in clinic al laboratory measurements in clinical trials 
of GNX.  In the completed PBO-controlled Phase 1, 2, and 3 studies, 0.3% of patients treated 
with GNX and 0.5% of patients treated with PBO exhibited elevated liver function tests during 
the study (aspartate aminotransferase [AST] or alanine aminotransferase [ALT] > 3 Ã— the upper 
limit of normal [ULN]).  There have been no cases of Hyâ€™s law considered to be rela ted to GNX 
in the GNX development program. 
In controlled clinical trials of GNX, 1.1% of patients receiving PBO and 1.7% of patients 
receiving GNX reported an adverse event (AE) of rash suggesting there is no obvious imbalance 
between drug and PBO in terms of frequency of this AE.  However, in PBO-controlled studies, rash led to discontinuation in GNX-treated patients in 6 cases (0.6%) compared to no cases (0%) in PBO-treated patients.  Most rashes improved either while the drug was continued or following discontinuation.  Two patients participating in the Phase 2 study investigating GNX in treatment 
of epi[INVESTIGATOR_59678] a serious adverse event (SAE) of rash.  Both events resolved after 
discontinuation of the investigational product (IP). 
Pediatric Safety Marinus has completed 2 double-blind (DB), randomized trials and 5 open-label (OL), 
uncontrolled clinical trials of GNX in the pediatric population.  One additional pediatric trial, OL Study 1042-0900 in children with various genetic epi[INVESTIGATOR_59679], is clinically complete and analysis is ongoing. 
Approximately 250 pediatric patients aged 4 months to 17 years (data cutoff [ADDRESS_64702] 2019) have 
received at least [ADDRESS_64703] cohorts received 12 to 54 mg/kg/day, although 
some patients received doses as high as 63 mg/kg/day or 1800 mg/day for adolescents.   
The majority of the pediatric patients were refractory epi[INVESTIGATOR_59680] (range 1-8).  Overall, GNX was generally safe and well tolerated.  In the incomplete crossover Study 1042-0500 (N = 56; all patients received GNX 
during the trial), 39 patients with IS treated with GNX doses up to 54 mg/kg/day for up to 
[ADDRESS_64704] frequently reported AEs ( â‰¥ 8% of patients) were 
vomiting (7 patients), somnolence (5 patients), a nd cough (5 patients).  Most AEs were mild or 
	
		

 
Confidential  Page 34 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
moderate; [ADDRESS_64705] frequent AEs noted were vomiting (11% in both GNX and PBO groups) and cough (8% GNX, 5% PBO).  Other AEs attributed to GNX included flatulence, insomnia, irritability, lethargy, and somnolence.  Adverse events reported in the other uncontrolled refractory pediatric epi[INVESTIGATOR_59681].   
In another randomized, DB, PBO-controlled study of 59 patients (aged 5-17 years) with FXS 
who were treated with GNX up to 36 mg/kg/day (maximum 1800 mg/day) or PBO, the percentage of patients who reported at least 1 TEAE was comparable between the treatment groups (85.2% versus 83.1% in the PBO and GNX treatment groups, respectively).  The most frequently reported TEAEs among patients who received GNX included fatigue 
(29/59 patients; 49.2%), somnolence (20/59 patients; 33.9%), vomiting (8/59 patients; 13.6%), decreased appetite (8/59 patients; 13.6%), aggression (6/59 patients; 10.2%) and rash 
(5/59 patients; 8.5%).  Both fatigue (49.2% vs 20.4%) and somnolence (33.9% vs 5.6%) 
occurred more frequently in GNX-treated patients compared with PBO-treated patients, 
respectively.  
Among patients who received PBO, headache (6 patients; 11.1%) and agitation 
(8 patients; 14.8%) were reported more frequently compared with GNX-treated patients.  Severe 
TEAEs were reported for 3/59 (5.1%) GNX patients and 1/54 (1.9%) PBO patients.  Severe 
events in the GNX group were somnolence and fatigue in [ADDRESS_64706] to vital signs, ECG, physical/neurological examinations, or clinical laboratory measures. 
2. STUDY OBJECTIVES AND PURPOSE 
2.1. Rationale for the Study 
GABAergic signaling may play a meaningful role in the development and severity of 
TSC-related epi[INVESTIGATOR_002], possibly due to altered expression of endogenous GABA A receptor 
modulators ( Di Michele et al., 2003 ).  There is evidence supporting a deficiency of the 
neuroactive steroid, 3 Î±, 5Î±-tetrahydroprogesterone (THP), or allopregnanolone, as a contributor 
to epi[INVESTIGATOR_59658].  Allopregnanolone is a positive modulator of the GABA A receptor 
and has been shown to have antiepi[INVESTIGATOR_59682].  There is a 
decrease in allopregnanolone relative to its functional GABA A antagonist, 3 Î²-THP, in patients 
with TSC-related epi[INVESTIGATOR_59683] (Di Michele et al., 2003 ).  This reduced ratio could alter neuronal excitability mediated by 
[CONTACT_59716]
A receptors, leading to the development of epi[INVESTIGATOR_002].  The role of GABA A receptor 
mediation is also supported by [CONTACT_59717], a specific and irreversible inhibitor of GABA-aminotransferase, in seizures due to TSC relative to other epi[INVESTIGATOR_31629] (Di Michele et al., 2003 ).  These findings provide compelling evidence for the potential role of 
neuroactive steroids with anticonvulsant properties, or analogues such as GNX, in the treatment of TSC-related epi[INVESTIGATOR_002]. 
	
		
 
Confidential  Page [ADDRESS_64707] 
from benzodiazepi[INVESTIGATOR_59684] ( Carter et al., 1997 ).  Ganaxolone has protective activity 
in diverse rodent seizure models ( Bialer et al., 2010; Reddy and Rogwski, 2012 ).  Clinical 
studies have demonstrated that GNX has anticonvulsant activity with an acceptable safety and 
tolerability profile in the dose range of 900 to 1800 mg given orally in adults and children 
(Kerrigan et al., 2000 ; Laxer et  al., 2000; Pi[INVESTIGATOR_59662]., 2007; Sperling et al., 2017 ).  Further, 
GNX reduces seizures in children with IS and refractory pediatric epi[INVESTIGATOR_002].  In an OL study, pediatric patients aged 2 to 60 months with refractory seizures and a history of IS were treated with GNX doses up to 36 mg/kg for up to 3 months ( Kerrigan et al., 2000 ).  Fifteen patients with 
a history of IS completed treatment.  Five of the 15 patients had a decrease from baseline in the number of spasms of â‰¥  50%, 5 had a decrease of 25% to 50%, and 5 had a decrease of < 25%.  
One patient became spasm-free and 1 non-responder (with a decrease of < 25%) was spasm-free 
from Weeks 2 to 7.   
A DB study (Study 1042-0500) of GNX in IS was also conducted.  In this study, patients aged 4 
to 24 months with IS received PBO or GNX doses of up to 54 mg/kg/day for up to 20 days in an 
incomplete crossover design.  A total of 55 of the 57 patients completed treatment, 54 of whom 
continued GNX treatment in Study 1042-0501, an open-label extension (OLE).  Although the 
GNX group had numerically higher reductions in frequency of spasm clusters, no statistically significant differences were observed in change from baseline between the treatment groups in 
the frequency of spasm clusters or in any of the secondary efficacy parameters at the end of the DB period (Day 9 Â± 1 day). 
In addition to its anticonvulsant activity, GNX has been shown to reduce anxiety, hyperactivity, 
and attention in children with FXS who had higher baseline levels of anxiety ( Ligsay et al., 
2016).  Similar behavioral problems occur in indivi duals with TSC, with rates of approximately 
50% for attention deficit hyperactivity disorder and autism ( JÃ¼lich and Sahin, 2014 ). 
It is hypothesized that GNX treatment will increase and improve GABA
A-receptor mediated 
signaling by [CONTACT_59731] . 
This present study is planned to assess prelimin ary safety and efficacy of GNX as adjunctive 
therapy for the treatment of primary seizure types in patients with genetically- or 
clinically-confirmed TSC-related epi[INVESTIGATOR_59685] 12-week treatment period.  Pharmacokinetic assessments and population PK an alyses will also be performed during this 
time.  The 12-week treatment period (4-week titr ation and 8-week maintenance periods) will be 
followed by [CONTACT_59732]-term OLE period.  Efficacy, safety and tolerability, and PK 
assessments will continue to be performed.  
2.2. Study Objectives 
2.2.1. Primary Objective 
The primary objective of this study is to asse ss preliminary safety and efficacy of GNX as 
adjunctive therapy for the treatment of primary seizure types in patients with genetically- or clinically-confirmed TSC-related epi[INVESTIGATOR_59685] 12-week treatment period.  The 
	
		
 
Confidential  Page 36 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
primary seizure types (defined later) are identified to be the most common, easily 
identifiable/countable by a parent/caregiver/legally authorized representative (LAR), and most consequential to the patientâ€™s quality of life.  
2.2.2. Secondary Objectives 
The secondary objectives of this study are the following:  
x To assess the long-term efficacy of GNX when administered as adjunctive therapy 
throughout the OLE period (Part B). 
x To assess the long-term safety and tolerability of GNX when administered as adjunctive 
therapy throughout the OLE period (Part B).  
  
 
  
 
  
 
   
  
  
3. STUDY DESIGN 
3.1. Study Design and Flow Chart 
This is an OL proof of concept study of adjunctive GNX treatment in patients with a confirmed 
clinical diagnosis of TSC and/or a mutation in either the TSC1  or TSC2 gene.  The trial consists 
of two parts:  Part A consists of a 4-week baseline period followed by a 12-week treatment 
period (4-week titration and 8-week maintenance).  For patients not continuing in the OLE period (Part B), a 2-week taper period followed by a 2-week safety period would follow.  The main difference between Part A and Part B is the length of treatment, less frequent assessments, and the ability to alter drug doses (both GNX and other AED treatments which includes initiating 
and stoppi[INVESTIGATOR_59686] r medications) based on investigator evaluation of the patientâ€™s clinical course 
during Part B.  Patients with a seizure frequency reduction rate of â‰¥ 35% during the 12 -week 
treatment period in Part A compared to baseline may continue into Part B (â€œOLE eligibleâ€).  If 
the investigator believes there is a medical benefit for the patient who does not meet the seizure reduction criterion to enter the OLE, they must discuss the patient with the sponsor medical monitor and receive sponsor approval for that patient to continue into the OLE.
  
Part A 
x 4-week baseline period 
	
		

 
Confidential  Page 37 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x 4-week titration period 
x 8-week maintenance period  
x 2-week taper period (For patients who do not complete Part A or after completing Part A 
but do not continue into Part B) 
x 2-week safety follow-up visit post taper (For patients who taper off GNX) 
Part B (Optional for OLE-eligible patients) 
x OLE period (until the Sponsor markets ganaxolone or terminates the study  
x 2-week taper period (For patients who discontinue GNX due to early termination or completion) 
x 2-week safety follow-up visit post-taper (For patients who taper off GNX) 
Figure 1: Study Design 
 
 
GNX = ganaxolone  
During the screening visit, each patientâ€™s baseline  
 will be collecte d and analyzed for post-study evaluation. 
Patient rescreening is allowed as agreed by [CONTACT_59718] a general concern for patient safety or an inability for the patient to become eligible (e.g., GNX allergy, sensitivity or exposure, non-TSC and/or other ineligible epi[INVESTIGATOR_002], chronic prohibited medical condition or treatment).  Subsequent screening should take place at least 30 days from the patientâ€™ s last visit, unless otherwise noted. 
Part A includes a 4-week baseline and 4 weeks of IP titration followed by 8 weeks of dose 
maintenance followed by 2-week taper for those patients not continuing into the Part B OLE 
period.  After meeting all eligibility criteria, approximately 30 patients aged 2 to 65 years 
(inclusive) with TSC-related epi[INVESTIGATOR_59687] a total of 12 weeks (4-week titration, 8-week maintenance) in additi on to their standard anti-seizure medication(s) 
(ASMs).  Patients will be titrated to 63 mg/ kg/day (maximum 1800 mg/day) over 4 weeks, and 
then maintained at that dose for another 8 weeks.  Patients who are not able to tolerate 63 mg/kg/day (or maximum 1800 mg/day) may be maintained on a lower dose after discussion with the sponsor medical monitor.  A minimum dose of 33 mg/kg/day or 900 mg/day is generally required during the maintenance period. 
For Part A, dose changes including alternative dosing paradigm (e.g., lower dose during the 
daytime and higher dose in the evening) should be discussed with the sponsor medical monitor 

	
		

 
Confidential  Page 38 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
prior to making the change or within 48 hours of making the change.  Patients who discontinue 
GNX should undergo a 2-week taper period, unless otherwise medically indicated.  Patients who discontinue GNX before the completion of the maintenance period will continue to be followed per protocol and, at a minimum, patients will be encouraged to maintain daily seizure diaries until the maintenance period in Part A is completed.  These patients will also return to the site 2 weeks after the taper for safety follow-up assessments. 
After completing the initial 16-week period, Part A, patients with a seizure reduction of â‰¥ 35% 
compared to the 4-week baseline period and who do not have any other contraindications for 
continued treatment can continue to be treated with GNX in the OLE period (Part B).  Patients will continue GNX treatment at the dose that they were taking at completion of Part A.  Doses of 
other ASMs may be adjusted (including tapering and initiating treatments) during Part B based on investigator discretion.  Any patient who discontinues GNX treatment should undergo a 2-week drug de-escalation (taper) period and return to the site 2 weeks later for safety follow-up 
assessments.   
Patients will be required to complete a daily diary to determine GNXâ€™s effect on seizures.  Days 
without seizures should also be noted.  Additional clinicia n- and caregiver-administered 
instruments will be used to assess th e efficacy of GNX in TSC, and will include:
   
x Caregiver Global Impression of Change (CGI-C) â€“ Target Behavior 
x Clinical Global Impression â€“ Improvement (CGI-I) caregiver and CGI-I clinician. 
3.2. Duration and Study Completion Definition 
After 4 weeks of baseline seizure charting, pa tients will initiate a 4- week GNX titration period 
followed by [CONTACT_1629] 8-week GNX maintenance period (Part A).  Patients completing Part A and deemed eligible for Part B will continue tak ing GNX for an add itional 24 weeks of treatment.  
Anyone discontinuing GNX w ill undergo a 2-week taper and a 2-week follow-up safety visit.  
Patients who discontinue IP treatment before the completion of the maintenance period in Part A 
will continue to be followed per protocol and at minimum maintain  daily seizure diary entry until 
the maintenance period is completed.   
The planned study duration will be approximately 64 weeks for patients who stay on the study 
through Part B, or until ganaxolone is commercially available.   
3.3. Sites and Regions 
This multicenter study is to be conducted at approximately 6 sites in the [LOCATION_002] (US).   
3.4. Discussion of Study Design 
Dosing will be based on doses that have been shown to be safe in children and adults in multiple 
studies with normal volunteers and individuals with epi[INVESTIGATOR_002].   In this current study, patients will  
receive OL GNX,  prescribed in increments of 15 mg/kg/day up to 63 mg/kg/day given as an oral 
suspension with food, during a 4-week titration period, 8-week maintenance period, and optional 
extension period.  Patients weighing â‰¤ 28 kg will be dosed on an mg/kg basis.  Patients weighing 
> 28 kg will be dosed on a fixed regimen in increments of 450 mg/day up to 1800 mg/day.   
Ganaxolone will be administered during the 4-week titration period as follows: 
	
		
 
Confidential  Page 39 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
1. For patients weighing â‰¤  28 kg (62 lbs): 
x 6 mg/kg three times daily (TID) (18 mg/kg/day) suspension - Days 1-7 
x 11 mg/kg TID (33 mg/kg/day) suspension - Days 8-14 
x 16 mg/kg TID (48 mg/kg/day) suspension - Days 15-21 
x 21 mg/kg TID (63 mg/kg/day) suspension - Days 22-28 
 
2. For patients weighing > 28 kg (62 lbs): 
x 150 mg TID (450 mg/day) suspension - Days 1-7 
x 300 mg TID (900 mg/day) suspension - Days 8-14 
x 450 mg TID (1350 mg/day) suspension - Days 15-21 
x 600 mg TID (1800 mg/day) suspension - Days 22-28 
Any patient not tolerating the next dose step can be maintained at the lower dose step for 
additional days before advancing to the next dose.   If the next dose is still not tolerated, the 
patient can drop back to the next lower dose step.  A minimum dose of 33 mg/kg/day or 900 mg/day is generally required following the escalation period and during the maintenance 
period. 
Patients will initiate treatment in Part B with GNX at the same dose they were on at the 
completion of the maintenance period.  During the extension period, doses of GNX may be adjusted to a maximum of 600 mg TID for patients weighing > 28 kg and a maximum dose of 21 mg/kg TID for patients â‰¤ 28 kg. 
4. STUDY POPULATION 
Each patientâ€™s parent/LAR must participate in the informed consent process and provide written 
informed consent (and/or patient assent) before any procedures specified in the protocol are performed.  
4.1. Inclusion Criteria (Part A) 
The patient will not be considered eligible for the study without meeting all the criteria below.  
1. Clinical or mutational diagnosis of TSC consistent with Northrup and Krueger, 2013 .  
a. Molecular confirmation of a pathogenic mutation in TSC1 or TSC2 .  A pathogenic 
mutation is defined as a mutation that clearly prevents protein synthesis and/or 
inactivates the function of the TSC1  or TSC2 proteins (e.g., nonsense mutation or 
frameshift mutations, large genomic deletions) or is a missense mutation whose effect 
on protein function has been established by [CONTACT_59733].  The investigator 
must review the results of the genetic analysis and confirm that the causal relationship 
to the epi[INVESTIGATOR_59665].  OR 
	
		
 
Confidential  Page 40 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
b. Clinical diagnosis of definite TSC which includes two major features or one major 
feature with â‰¥ [ADDRESS_64708] document which of the features 
(Major or Minor) fulfill the clinical diagnostic criteria.    
 
Major features Minor features 
1. Hypomelanotic macules ( â‰¥ 3, 
at least 5-mm diameter) 
2. Angiofibromas (â‰¥ 3) or fibrous 
cephalic plaque 
3. Ungual fibromas ( â‰¥ 2) 
4. Shagreen patch 
5. Multiple retinal hamartomas 
6. Cortical dysplasias a 
7. Subependymal nodules 
8. Subependymal giant cell 
astrocytomas 
9. Cardiac rhabodomyoma 
10. Lymphangioleiomyomatosis 
(LAM) b 
11. Angiomyolipomas (â‰¥ 2) b 1. â€œConfettiâ€ skin lesions  
2. Dental enamel pi[INVESTIGATOR_10022] ( â‰¥ 3) 
3. Intraoral fibromas ( â‰¥ 2) 
4. Retinal achromic patch 
5. Multiple renal cysts 
6. Nonrenal hamartomas 
a. Includes tubers and cerebral white matter radial migration lines 
b. A combination of the two major clinical features (LAM and angiomyolipomas) without other features that does not meet 
criteria for a definite diagnosis. 
 
2. Male or female patients aged 2 through 65 years, inclusive. 
3. Patient/parent/caregiver or LAR willing to give written informed consent/assent, after 
being properly informed of the nature and risks of the study and prior to engaging in any 
study-related procedures.  Assent for patients over [ADDRESS_64709] 8 countable/witnessed primary seizures during the 4-week baseline period 
with at least [ADDRESS_64710] 3 of the 4 weeks of baseline.  The 
primary seizure types are defined as the following:  focal motor seizures without impairment of consciousness or awareness, focal seizures with impairment of consciousness or awareness, focal seizures evolving to bilateral, tonic-clonic convulsive seizures, and generalized motor seizures including tonic-clonic, bilateral tonic, bilateral clonic, or atonic/drop seizures.  Focal aware non-motor and generalized seizures without motor features, infantile or epi[INVESTIGATOR_59666], and myoclonic seizures do not count as the primary seizure types. 
6. Patient must be approved to participate by [CONTACT_3552] (e.g., Epi[INVESTIGATOR_59667]) after review of medical history, gene tic testing, and patientsâ€™ seizure types.  
	
		
 
Confidential  Page 41 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
7. Patients should be on a stable regimen of ASMs at therapeutic doses for â‰¥ 1 month prior 
to the screening visit, without a foreseeable change in dosing for the duration of Part A.  
Vagus nerve stimulator (VNS), ketogenic diet , and modified Atkins diet should be 
unchanged for 3 months prior to screening and will not count towards the number of 
ASMs. 
8. Patients with surgically implanted VNS will be allowed to enter the study provided that 
all of the following conditions are met: 
a. The VNS has been in place for â‰¥ [ADDRESS_64711] for the duration of baseline and Part A. 
9. Parent/caregiver is able and willing to mainta in an accurate and complete daily seizure 
diary for the duration of the study. 
10. Able and willing to take IP (suspension) with food 3 times daily.  (GNX must be 
administered with food).  
11. Sexually active female of childbearing potential must be using a medically acceptable 
method of birth control and have a negative quantitative serum Î²-human chorionic 
growth hormone (Î² -HCG) test collected at the initial screening visit.  Childbearing 
potential is defined as a female who is biologically capable of becoming pregnant.  A 
medically acceptable method of birth control includes intrauterine devices in place for at 
least 3 months prior to the screening visit, surgical sterilization, or adequate barrier methods (e.g., diaphragm or condom and foam).  An oral contraceptive alone is not considered adequate for the purpose of this study.  Use of oral contraceptives in combination with another method (e.g., a spermicidal cream) is acceptable.  In patients who are not sexually active, abstinence is an acceptable form of birth control. 
4.1.1. Inclusion Criterion (Part B) 
1. Patients have experienced â‰¥ 35% reductio n in primary seizure frequency during the Part 
A treatment period compared to the 4-week Baseline Period. 
4.2. Exclusion Criteria (Part A) 
Patients are excluded from the study if any of the following criteria apply: 
1. Previous exposure to GNX. 
2. Pregnant or breastfeeding. 
3. Concurrent use of strong inducers or inhibitors of cytochrome P450 (CYP)3A4/5/7.  Any strong inhibitor or inducer of CYP3A4/5/[ADDRESS_64712] positive for tetrahydrocannabinol (THC) or non-approved CBD via 
plasma drug screen.  
	
		
 
Confidential  Page 42 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
6. Chronic use of oral steroid medications, ketoconazole (except for topi[INVESTIGATOR_29899]), 
St. Johnâ€™s Wort, or other IPs is not permitted.  
7. Adrenocorticotropic hormone (ACTH), prednisone, or other systemically administered (non-inhaled) steroids must be discontinued > 28 days prior to screening.  Concomitant topi[INVESTIGATOR_2855], inhaled or intranasal steroids are allowed and do not warrant exclusion from the 
study.  
8. Changes in any chronic medications within the month (e.g., 30 days) prior to the 
screening visit.  All concomitant medications must have been at a stable in dose for at least 1-month prior to the screening visit unless otherwise noted. 
9. Patient is being considered for epi[INVESTIGATOR_59668] [ADDRESS_64713] any disease or condition (medical or surgical; other than TSC) at the screening visit 
that might compromise the hematologic, cardiovascular, pulmonary, renal, 
gastrointestinal, or hepatic systems; or other conditions that might interfere with the 
absorption, distribution, metabolism, or excretion of the IP, or would place the patient at 
increased risk.  This may include any illness in the past [ADDRESS_64714]/serum glutamic oxaloacetic transaminase (SGOT) or ALT/serum glutamic 
pyruvic transaminase (SGPT) >3 Ã— the ULN at screening or baseline visits and confirmed by a repeat test.   
13. Total bilirubin levels > 1.5 Ã— ULN at screening or baseline visit and confirmed by a repeat test.  In cases of documented, stable medical condition (i.e., Gilbertâ€™s Syndrome) 
resulting in levels of total bilirubin > ULN, the medical monitor can determine if a 
protocol exception can be made. 
14. Patients with significant renal insufficienc y, estimated glomerular filtration rate (eGFR) 
< 30 mL/min (calculated using the Cockcroft-Gault formula or Pediatric GFR calculator 
or Bedside Schwartz), will be excluded from study entry or will be discontinued if the criterion is met post baseline. 
15. Have been exposed to any other investigational drug within 30 days or fewer than 
5 half-lives (whichever is shorter) prior to the screening visit.   
16. Unwillingness to withhold grapefruit, Seville oranges, star fruit, or grapefruit containing 
products from diet [ADDRESS_64715] had an active suicidal plan/intent or active suicidal thoughts in the past [ADDRESS_64716] 3 years.   
18. Known sensitivity or allergy to any component in the IP(s), progeste rone or other related 
steroid compounds. 
	
		
 
Confidential  Page 43 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
4.2.1. Exclusion Criterion (Part B) 
1. Patient developed a medical condition that would make it unsafe for patients to received 
GNX as determined by [CONTACT_093]. 
4.3. Restrictions  
Patients must abstain from the use of alcohol, and from consuming grapefruit, Seville oranges, starfruit, or grapefruit containing products from [ADDRESS_64717] dose and for the duration of the study. 
4.4. Reproductive Potential 
4.4.1. Female Contraception 
Sexually active girls/women of childbearing poten tial should be using a medically acceptable 
form of birth control and have a negati ve quantitative serum Î²-HCG test collected at the initial 
screening visit.  Girls/women of childbearing potential must be advised to use medically acceptable birth control t hroughout the study period a nd for [ADDRESS_64718] 3 months prior to the screening visit, surgical sterilization, or adequate barrier methods (e.g., diaphragm or condom and foam).  An oral contraceptive alone is not considered adequate for the 
purpose of this study.  Use of oral contraceptives in combination with another method (e.g., a 
spermicidal cream) is acceptable.  Contraceptive measures such as Plan B
TM, sold for emergency 
use after unprotected sex, are not acceptable methods for routine use.  Patients who are not 
sexually active, abstinence is an acceptable form. 
4.4.2. Male Contraception 
Male patients must agree to take all necessary measures to avoid causing pregnancy in their 
sexual partners during the study and for [ADDRESS_64719] dose of IP.  Medically acceptable 
contraceptives include surgical sterilization (such as a vasectomy) and a condom used with a 
spermicidal gel or foam.   
Male patients should not donate sperm during the study and for [ADDRESS_64720] dose of IP.  
Patients who are not sexually active, abstinence is an acceptable form. 
4.5. Discontinuation of Patients 
A patient may withdraw - or their parent/LAR may withdraw the patient - from the study at any time for any reason without prejudi ce to their future medical care by [CONTACT_59734][INVESTIGATOR_307].  The investigator or sponsor may withdraw the patient at any time (e.g., in the interest of patient safety).  The investigator is encouraged to discuss withdrawal of a patient from IP with the medical monitor when possible. 
If the IP is discontinued at any time, patients should follow the 2-week taper schedule unless 
otherwise medically indicated such as drug-induced rash.  If the patient discontinues during the maintenance period of Part A, evaluations listed for Taper and Safety Visit ( Section 7.2.8) are to 
be performed as completely as possible.  If the patient discontinues during the OLE period (Part B), evaluations listed for the Taper Visit ( Section 7.3.2 ) and Safety Follow-up Post Taper 
	
		
 
Confidential  Page 44 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Visit (Section 7.3.4) are to be performed as completely as possible.  Comments (spontaneous or 
elicited) or complaints made by [CONTACT_59735].  The reason for termination, date of stoppi[INVESTIGATOR_59688], and total amount of IP taken must be recorded in the electronic case report form (eCRF) and source documents.  Discontinuation of IP due to AEs must also be reflected on the AE eCRF page. 
4.5.1. Patient Withdrawal Criteria 
All patients or his/her parent/LAR reserve the right to withdraw from the clinical study at any 
time, as stated in the informed consent/assent form .  The investigator may discontinue patients 
from the clinical study for any of the following reasons: 
x Patient is found to have entered the study in violation of the protocol; 
x Patient requires the use of a disallowed concomitant medication; 
x Patientâ€™s condition changes after entering the clinical investigation so that the patient no longer meets the inclusion criteria or develops any of the exclusion criteria; 
x Patient or parent/LAR withdraws consent or assent to participate in the study; 
x Patient is noncompliant with the procedures set forth in the protocol; 
x Patient experiences an AE/SAE that warrants withdrawal from the study;  
x Laboratory, medical, or clinical finding for which clinical intervention should take precedence over study participation; or 
x It is the investigatorâ€™s opi[INVESTIGATOR_59689]â€™s best interest to continue in the 
study. 
Decisions to discontinue the study will be made at each participating site by [CONTACT_093].  If 
feasible, the reason for discontinuation should be discussed with the sponsorâ€™s medical monitor prior to patientâ€™s discontinuation.  Patients who discontinue IP during th e maintenance period of 
Part A will continue to record daily seizure frequency at minimum until the completion of the 
maintenance period. 
4.5.2. Reasons for Early Discontinuation 
The reason for early discontinuation must be determined by [CONTACT_59736]â€™s source documents and on the eCRF.  If a patient is withdrawn for more than [ADDRESS_64721] clinically relevant 
reason should be entered on the eCRF.  
Reasons for early termination include but are not limited to the following: 
x AE 
x Protocol violation/protocol deviation 
x Withdrawal by [CONTACT_49708]/LAR 
x Lost to follow-up 
x Lack of efficacy 
	
		
 
Confidential  Page 45 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Death 
x Physician decision 
x Other (must be specified in the patient source document and eCRF)  
4.5.3. Patients Lost to Follow-up Prior to Last Scheduled Visit 
A minimum of [ADDRESS_64722] (office visit or telephone contact).  At least [ADDRESS_64723] include a written communication sent to the patient â€™s last 
known address via courier or mail (with an acknowledgment of receipt request) asking that they return to the site for final safety evaluations and return any unused IP.  If contact [CONTACT_59737]-up visit, it should be documented in the eCRF. 
4.6. Patient Numbering 
During the screening visit, each patient will be assigned a unique 6-digit patient number by [CONTACT_39722].  The patient number will consist of a 3-digit clinical investigational site number assigned by 
[CONTACT_456], followed by a 3-digit patient number (e.g., 001) assigned by [CONTACT_5984].  This patient number will also serve as the screening number.  The unique 6-digit patient number will serve as the patient ID and be used to track the patient throughout the study. 
The clinical site is responsible for maintaining a current log of patient number assignments and 
bottle numbers of the IP administered to each patient.  The unique patient  number is required to 
be entered on all clinical investigation documentation (eCRFs, labeling of clinical materials and samples containers, drug accoun tability logs, etc.).   
5. EXCLUDED, PRIOR, AND CONCOMITANT MEDICATIONS 
The investigator should assess all concomitant medications at every visit, and at the screening 
visit in particular to ensure that the patient is not taking excluded medications.  
5.1. Prior Medications 
Prior medications include all treatment, including but not limited to herbal treatments, vitamins, 
surgical implants (such as VNS), and prescribe d medications received within 30 days (or PK 
equivalent of five half-lives, whichever is longer) of the date prior to screening.  Prior treatment 
information, if available, must be recorded on the appropriate eCRF page. 
5.2. Concomitant Medications 
Concomitant medications refer to all treatment taken between the date of Informed 
Consent/Assent and the date of the last dose of IP.  Concomitant treatment information must be 
recorded on the appropriate eCRF page.  Concomitant topi[INVESTIGATOR_59690].  If the patient is currently taking an excluded medication at the time of the screening 
	
		
 
Confidential  Page [ADDRESS_64724]. Johnâ€™s Wort is not permitted (See 
Section 12.1 ). 
5.2.1. Concomitant AED Medications 
Patients in the study should be on a stable regimen of AED medications at therapeutic doses for 
â‰¥ 1 month prior to the screening vi sit, and cannot be changed at any time prior to Visit 5 during 
Part A, but may be adjusted during Part B.   
Vagus nerve stimulator, ketogenic diet, and modi fied Atkins diet should be unchanged for 3 
months prior to screening and will not count towards the number of ASMs. Patient with surgically implanted VNS will be allowed to enter the study provided that all of the 
following conditions are met: 
x The VNS has been in place for â‰¥ [ADDRESS_64725] 1 year, and has had stable liver function (AST/ALT) and hematology during the course of treatment, and is expected to remain constant throughout the 12-week treatment period. 
5.3. Rescue Medications 
The use of rescue medication is allowed.  The type, dose, date, and frequency will be recorded. 
5.4. Excluded Medications 
Excluded medications include all steroid medications, other IPs, as well as ketoconazole, and St. Johnâ€™s wort.  Concurrent use of AC TH, prednisone or othe r glucocorticoid is not permitted, nor 
use of moderate or strong inducers or inhibitors of CYP3A4/5/7.  Patients on ACTH, prednisone, 
or other systemically (non-inhaled) administered steroids should be off the product greater than 
28 days prior to screening.  Any strong inhibitor or inducer of CYP3A4/5/[ADDRESS_64726] of CYP3A4/5/7 inhibitors and inducers is included in Section 12.1 .  Concomitant topi[INVESTIGATOR_59691].   
Products containing THC or non-approved CBD are excluded in the treatment period (Part A) of 
the study but allowed in the OLE period (Part B).  Tetrahydrocannabinol or non-approved CBD 
should be washed out for at least 6 weeks.  Patients with a positive result on THC at the 
	
		
Confidential Page [ADDRESS_64727] 
Drug name:  [CONTACT_59770]:  Catalent Pharma Solutions, Somerset, NJ [ZIP_CODE] [LOCATION_003] Vehicle:  The suspension contains GNX (50 mg/mL), hydroxypropyl methylcellulose, polyvinyl 
alcohol, sodium lauryl sulfate, simethicone, methylparaben, propylparaben, sodium benzoate , 
citric acid, and sodium citrate at pH  to , and is sweetened with sucralose and flavored with 
artificial cherry.   
Strength:  50 mg/mL suspension  Ganaxolone will be supplied at a concentration of 50 mg/mL (GNX equivalent) in 120 mL 
bottles, containi ng 110 mL GNX.   
All IP will be stored at the research pharmac y prior to dispensing, or in a locked cabinet 
accessible only to members of the investigative re search team after the completion of each study 
visit.  Study medication should be stored at room temperature 15Â°C to 25Â°C (59Â°F to 77Â°F). 
6.1.1. Blinding the Treatment Assignment 
This is an OL study. 
6.2. Administration of Investigational Products 
6.2.1. Allocation of Patients to Treatment 
All eligible patients will receive treatment with GNX in this OL study.  
6.2.2. Dosing 
Ganaxolone will be administered in increments of 15 mg/kg/day up to 63 mg/kg/day (maximum 
1800 m g/day) given as an oral suspension with food.  Patients weighing â‰¤ 28 kg will be dosed on 
an mg/kg basis.  Patients weighing > 28 kg will be dosed on a fixed regimen in increments of 
450 mg/day up to 1800 mg/day.  All IP prescribed per day will be administered in 3 divided 
doses following a meal or snack.  Ganaxolone is to be administered during the 4-week titration 
period as follows: 
	
		

 
Confidential  Page 48 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Table  3: Oral Suspension Dosinga for Patients Weighing â‰¤ 28 kg (62 lbs)b 
Dose mg/kg Total mg/kg/day Days 
6 TID 18 1-7 
11 TID 33 8-14 
16 TID 48 15-21 
21 TID 63 22-28 
TID = three times daily 
a. To be administered in 3 divided doses following a meal or snack. 
b. Patients weighing â‰¤ 28 kg will be dosed according to the patientâ€™s weight in kilograms.  
 
Table  4: Oral Suspension Dosinga for Patients Weighing > 28 kg (62 lbs)b 
Dose mg ml per Dose Total mg/day Days 
150 TID 3 450 1-7 
300 TID 6 900 8-14 
450 TID 9 1350 15-21 
600 TID 12 1800 22-28 
TID = three times daily 
a. To be administered in 3 divided doses following a meal or snack. 
b. Patients weighing > 28 kg will be dosed on a fixed regimen in increments of 450 mg/day up to 1800 mg/day. 
 
Any patient not tolerating the next dose step can be maintained at the lower dose step for 
additional days before advancing to the next dose.   If the next dose is still not tolerated, the 
patient can drop back to the next lower dose step.  A minimum dose of 33 mg/kg/day or 900 mg/day is generally required following the escalation period, during the maintenance period.   
Dose changes including alternative dosing pa radigms (e.g., lower dose during the daytime and 
higher dose in the evening) should be discussed with the sponsor medical monitor prior to 
making the change or within [ADDRESS_64728] the sponsor medical monitor to discuss 
continued IP dosing.  Patients who discontinue GNX treatment before the completion of the maintenance period in Part A will continue to be followed per protocol and, at a minimum, patients will be encouraged to maintain daily se izure diary entries until Part A is completed. 
Patients who meet all of the inclusion criteria and none of the exclusion criteria will initiate treatment in Part B with GNX at the same dose they were on at the completion of Part A.  During Part B, doses of GNX may be adjusted to a maximum of 600 mg TID for patients weighing > 28 kg and a maximum dose of 21 mg/kg TID for patients we ighing â‰¤ 28 kg.  
[IP_ADDRESS]. De-escalation Period 
Any patient who discontinues IP treatment should undergo a 2-week drug de-escalation (taper) 
period, unless otherwise medically indicated such  as drug-induced rash.  The schedule will be 
dependent on the maintenance dose.  Typi[INVESTIGATOR_897], doses will be reduced by 15 mg/kg/day or 450 
	
		
 
Confidential  Page 49 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
mg/day every [ADDRESS_64729] be taken 
with a meal or snack .  Note:  grapefruit and grapefruit juice, Seville oranges and star fruit are 
prohibited during the study.  
Ganaxolone oral suspension will be administered through an or al dosing syringe administered 
by [CONTACT_3654]/caregivers TID, following the morning, noon, and evening meal or snack.  Each dose 
should be separated by a minimum of 4 hours and a maximum of 12 hours.  A missed dose of IP may be taken up to 4 hours before the next scheduled dose; otherwise, the missed dose should not be given.  
Prior to each dose, the following instructions should be followed:  
1. Manually shake bottle end to end, 2-3 times per second, for 1 minute 
 
2. Allow the bottle to stand for 1 minute  
3. Attach the dosing apparatus (adaptor with syringe), invert the bottle and remove the 
indicated dose  
4. Administer dose as indicated  
Please use a new dosing syringe and adapter every day.  Dosing syringes should be cleaned with 
hot water rinse and air-drying between first, second, and third daily doses.  
Patients and their parent or legal  guardian will be informed about possible side effects from the 
IP and cautioned to avoid quick postural changes, at least until they know how the IP affects 
them.  Patients will be advised that the IP might affect mental alertness.  They will also be cautioned that non-adherence to the dosing instructions (e.g., increasing the dose, taking the IP doses too close together) could produce side effects.  
6.2.4. Missing a Dose 
A missed dose of IP may be taken up to 4 hours before the next scheduled dose; otherwise, the 
missed dose should not be given. 
Parents/caregivers should be instructed that if the patient misses 2 days in a row or more, the site 
should be contact[CONTACT_59738].  
Parents/caregivers should be instructed to minimize the number of missed doses the patient 
experiences and be re-educated on proper dosing procedures at each visit to ensure that missed 
doses are avoided.   
6.3. Labeling, Packaging, Storage, and Handling 
6.3.1. Labeling 
Labels containing study information and bottle identi fication are applied to the IP container.  
All IP is labeled with a minimum of the following:  protocol number, medication identification 
number (if applicable), dosage form (including product name [CONTACT_38933]), directions 
	
		
 
Confidential  Page 50 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
for use, storage conditions, batch number and/or packaging reference, the statements â€œFor 
investigational use onlyâ€ and/or â€œCaution:  Ne w Drug â€”Limited by [CONTACT_4496] (or US) Law to 
Investigational Useâ€ and â€œKeep out of reach of children,â€ and the sponsorâ€™s name [CONTACT_3816].  
Additional labels may, on a case-by-case basis, be applied to the IP in order to satisfy local or hospi[INVESTIGATOR_59692], but must not: 
x Contradict the clinical study label 
x Obscure the clinical study label 
x Identify the study patient by [CONTACT_2300], without consultation with the sponsor 
Additional labels may not be added without the sponsorâ€™s prior full agreement.  
6.3.2. Packaging 
Ganaxolone will be supplied as an oral suspension formulation.    
Ganaxolone for oral suspension formul ation will be provided to the site as individual suspension 
bottles containing 110 mL in 120-mL high-density polyethylene (HDPE) bottles.  Ganaxolone 
will be supplied at a concentration of 50 mg/mL.  
Changes to sponsor-supplied packaging prior to dosing may not occur without full agreement in 
advance by [CONTACT_456]. 
6.3.3. Storage 
The investigator has overall responsibility for ens uring that IP is stored in a secure, limited-
access location.  Limited responsibility may be delegated to the pharmacy or member of the 
study team, but this delegation must be documented.  Investigational products are distributed by 
[CONTACT_59739] a nominated member of the study team.  
Investigational product should be stored at room temperature 15Â°C to 25Â°C (59Â°F to 77Â°F).  
Excursions between 5Â°C (for less than 24 hours) and 40Â°C are acceptable.  If a temperature 
excursion below 5Â°C or above 40Â°C (41Â°F to 104Â°F) occurs, Marinus must be notified. 
Investigational product must be stored in accordance with labeled storage conditions.  
Temperature monitoring of the IP is required at the storage location to ensure that the IP is maintained within an established temperature range.  The investigator is responsible for ensuring that the temperature is monitored throughout the duration of the study and that records are maintained; the temperature should be monitored continuously by [CONTACT_28920]-house system, by a 
mechanical recording device such as a calibrated chart recorder, or by [CONTACT_3177], such that 
both minimum and maximum thermometric values over a specific time period can be recorded and retrieved as required.  Such a device (i.e., certified minimum/maximum thermometer) would require manual resetting upon each recording.  The sponsor must be notified immediately upon discovery of any excursion from the established range.  Temperature excursions will require site investigation as to cause and remediation.  Th e sponsor will determine the ultimate impact of 
excursions on the IP and will provide supportive documentation as necessary.  Under no circumstances should the product be dispensed to patients until the impact has been determined 
and the product is deemed appropriate for use by [CONTACT_456]. 
	
		
 
Confidential  Page [ADDRESS_64730](s), such as fumigation of a storage room. 
6.4. Investigational Product Accountability 
Investigators will be provided with sufficient amounts of the IP to carry out this protocol for the 
agreed number of patients.  The investigator or designee will acknowledge receipt of the IP, 
documenting shipment content and condition.  Accurate records of all IP dispensed, used, returned, and/or destroyed must be maintained as detailed further in this section. 
The investigator has overall responsibility for administering/dispensing IP.  Where permissible, 
tasks may be delegated to a qualified designee (e.g., a pharmacist) who is adequately trained in the protocol and who works under the direct supervision of the investigator.  This delegation must be documented in the applicable study delegation of authority form. 
The investigator or their designee (as documented by [CONTACT_1710]) will administer and/or dispense the IP only to patients included in 
this study following the procedures set out in the study protocol.  Each patient will be given only 
the IP carrying his or her treatment assignment.  All administered and/or dispensed IP will be 
documented on the eCRFs and/or other IP record.  The investigator is responsible for ensuring 
the retrieval of all IP and study supplies from patient .  
The patientâ€™s parent/caregiver must be instructed to save and bring their unused IP and 
empty/used IP packaging to the clinic and final follow-up visit or to ship it back to the site via 
secure courier.  Investigat ional product accountability must be assessed at the 
container/packaging level for unused IP that is contained within the original tamper-evident sealed container (e.g., bottles) or at the individual count level for opened containers/packaging.  The pharmacist/nominated person will record details on the IP accountability form. 
No IP stock or returned inventory from a Marinus-sponsored study may be removed from the site 
where originally shipped without prior knowledge and consent by [CONTACT_456].  If such transfer is 
authorized by [CONTACT_456], all applicable local, state, and national laws must be adhered to for the 
transfer. 
The sponsor or its representatives must be permitted access to review the supplies storage and 
distribution procedures and records.  
At the end of the study, or as instructed by [CONTACT_456], all unused stock, patient-returned, or 
expi[INVESTIGATOR_59693] a nominated contractor on behalf of the sponsor for destruction 
or are to be destroyed by [CONTACT_779].  Investigational products being returned to the sponsorâ€™s 
designated contractors or approved to be destroyed by [CONTACT_59740]/measured and verified will be reconciled by [CONTACT_38889] (or designated clinical research 
organization [CRO]).  Shipment return forms, when used, will be signed pr ior to shipment from 
the site.  Returned IPs will be packed in a ta mper-evident manner to ensure product integrity.  
Shipment of all returned IP must comply with local, state, and national laws. 
With the written agreement of the sponsor, unused stock, patient-returned, and expi[INVESTIGATOR_59694] a local facility.  In this case, destruction records identifying what was 
destroyed, when, and how must be obtained with copi[INVESTIGATOR_59695].  Destruction of 
IPs must be in accordance with local, state, and national laws. 
	
		
 
Confidential  Page 52 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Based on entries in the siteâ€™s drug accountability forms, it must be possible to reconcile IPs 
delivered with those used and returned.  All IPs must be accounted for and all discrepancies investigated and documented to the sponsorâ€™s satisfaction.  
6.5. Patient Compliance 
Patient compliance will be tracked through the se izure and medication diary.  Parent/caregiver 
are to record daily seizure frequency and type in addition to study medication and non-study AED administration.  Compliance with IP treatment will be assessed by [CONTACT_59741].  Parent/caregiver will be re-educated on the importance of adheri ng to daily seizure, IP and non-study AED 
recording as needed.  Patients that fall below 80% compliance at 2 consecutive visits during the maintenance  period will not be in the Pe r-Protocol (PP) population. 
7. STUDY PROCEDURES 
7.1. Study Assessments 
See Schedule of Assessments ( Table 1 and Table 2 ) for details regarding scheduled assessments 
and procedures in this study.  
Study Assessments can be conducted at the institution of the site Investigator or remotely at the 
patientâ€™s home. All assessments can be conducted remotely with the use of telemedicine video 
tools used by [CONTACT_7893]; and providing traveling nurses to take vital signs, draw blood samples, and collect specimens.  and ECGs can be completed by a mobile vendor that is contracted to perform these tasks. 
7.2. Study Procedures (Part A:  Treatment Period) 
7.2.1. Screening Period 
[IP_ADDRESS]. Screening (Visit 1, Week -4) 
Additional procedures/assessments to be completed during the screening period may include the following: 
x Informed consent from parent/LAR (or patient assent) 
x Demographics and medical history 
x Review of inclusion/exclusion criteria 
x Review previous genetic testing results to evaluate pathogenic or likely pathogenic TSC1  
or TSC2 variant.  If genetic testing has not previously been performed, then a biological 
sample will be obtained to complete genetic testing at the sponsorâ€™s designat ed lab.  
Note:  Tuberous Sclerosis Complex diagnosis does not require pathogenic TSC1 or TSC2  
mutations if the clinical criteria are met. 
x Seizure Identification and Diagnostic Review Form (SIF/DRF) (Epi[INVESTIGATOR_59669]) 
	
		

 
Confidential  Page 53 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Vital signs (to include blood pressure [BP], heart rate [HR], respi[INVESTIGATOR_697] [RR], and 
body temperature). 
x Height and weight.  Length will be measured if height cannot be obtained. 
x Physical, neurological, and developmental examination (developmental examination is 
limited to pediatric patients 2 to 17 years of age, inclusive) 
x Clinical laboratory tests (chemistry and hematology) 
x Urinalysis (an attempt should be made to collect a urine sample at this screening visit.  
Otherwise, the urine sample can be collected at baseline.) 
x Drug screen (plasma) for THC and CBD.  If the screening drug test is positive, the patient 
can be retested after two weeks.   
x Serum pregnancy test for all girls/women of childbearing potential  
x Tanner staging 
x Concomitant AED review and levels if per standard of care 
x  
x AEs 
x Seizure and medication diary set up and review.  Caregiver given seizure diary and instructions for use. 
A screen failure is a patient for whom informed consent/assent has been obtained and has failed to meet the inclusion criteria and/or met at least one of the exclusion criteria and has not been administered the IP.  
Patient rescreening is allowed as agreed by [CONTACT_59718] a 
general concern for patient safety or an inability for the patient to become eligible (e.g., GNX 
allergy, sensitivity or exposure, non-TSC and/or other ineligible epi[INVESTIGATOR_002], chronic prohibited 
medical condition or treatment).  Subsequent screening should take place at least 30 days from the patientâ€™s last visit . 
7.2.2. Baseline (Visit 2, Week 0 + 4 days) 
The 4 weeks between the Screening Visit and the Baseline Visit can be no less than 28 days and no more than 32 days.  The following study procedures/assessments are to be completed prior to 
IP administration: 
x Review of inclusion/exclusion criteria 
x Medical history review 
x Review genetic testing results for patients that were screened without previous genetic 
testing results and had a genetic test performed at the sponsorâ€™s designated lab  
x SIF/DRF (Epi[INVESTIGATOR_55610]) approval 
x Vital signs (to include BP, HR, RR, and body temperature) 
	
		

 
Confidential  Page 54 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Weight 
x Physical, neurological, and developmental examination (developmental examination is 
limited to pediatric patients 2 to 17 years of age, inclusive) 
x ECG 
x Clinical laboratory tests (chemistry and hematology) 
x Urinalysis (If the urine sample was not collected at screening, it must be collected at 
baseline) 
x Drug screen (plasma) for THC and CBD 
x Serum pregnancy test for all girls/women of childbearing potential 
x Concomitant AED review and levels if per standard of care 
x AEs 
x Seizure and medication diary review 
x  
x CGI-C (parent/caregiver/LAR identified behavioral target).  During the baseline visit, the 
investigator and parent/caregiver/LAR will decide on a domain and identify the specific 
behavior that the patient exhibits that denotes the domain.  This behavior will be used at 
subsequent visits to assess change after the initiation of IP. 
x CGI-I (parent/caregiver/LAR and clinician) 
x Columbia-Suicide Severity Rating Scale (C-SSRS) (baseline for m) for patients â‰¥ 7 years 
old if appropriate.  Otherwise clinical judgment will be used. 
x Dispense IP 
7.2.3. Telephone Follow-up (Day 1, 2 and 3 + 1 days) 
A telephone follow-up visit will be conducted each of the 3 (Â± 1) days after the Week 0 Baseline Visit to assess the following: 
x AEs 
x Seizure and medication diary review 
7.2.4. Titration Period (Visit 3, Week 1 Â± 3 days) 
The following study procedures/assessments will be completed at Week 1 (Â± 3 days): 
x Vital signs (to include BP, HR, RR, and body temperature) 
x Weight 
x Physical, neurological, and developmental examination (developmental examination is limited to pediatric patients 2 to 17 years of age, inclusive) 
x ECG  
	
		

 
Confidential  Page 55 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Clinical laboratory tests (chemistry and hematology) 
x Urinalysis 
x Concomitant AED review and levels if per standard of care 
x AEs 
x Seizure and medication diary review 
7.2.5. Titration Period (Phone Follow-ups, Weeks 2, 3, and 4 Â± 3 days) 
A telephone follow-up visit will be conducted at Weeks 2, 3, and 4 (Â± 3 days) to assess the 
following: 
x AEs 
x Seizure and medication diary review 
7.2.6. Maintenance Period (Visits 4 and 5, Weeks 5 and 12 Â± 3 days) 
The following study procedures/assessments will be completed at Weeks 5 and 12 (Â± 3 days): 
x Vital signs (to include BP, HR, RR, and body temperature) 
x Weight 
x Physical, neurological, and developmental examination (developmental examination is limited to pediatric patients 2 to 17 years of age, inclusive) 
x ECG  
x Clinical laboratory tests (chemistry and hematology) 
x Urinalysis 
x Drug screen (plasma) for THC and CBD (Visit 5 [Week 12]) 
x Serum pregnancy test for all girls/women of childbearing potential 
x IP PK sample (Visit 4 [Week 5], between 1-[ADDRESS_64731] IP dose and Visit 5 
[Week 12], between 4-[ADDRESS_64732] IP dose) 
x Concomitant AED review and levels if per standard of care 
x  
x AEs 
x Seizure and medication diary review 
x  
x CGI-C (parent/caregiver/LAR identified behavioral target) 
x CGI-I (parent/caregiver/LAR and clinician) 
x C-SSRS (since previous visit).  Only fo r patients â‰¥ 7 years old if appropriate, otherwise 
clinical judgement will be used. 
	
		

 
Confidential  Page 56 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Dispense IP 
7.2.7. Maintenance Period (Phone Follow-up, Week 9 Â± 3 days) 
A telephone follow-up visit will be conducted at Week 9 (Â± 3 days) to assess the following: 
x AEs 
x Seizure and medication diary review 
7.2.8. Taper and Safety Visits (Visit 5a, Week 16 Â± 3 days) 
For patients who do not continue into study Part  B, the following assessments will be completed 
after 2 weeks of taper and 2 weeks after completion of treatment (Â± 3 days): 
x Vital signs (to include BP, HR, RR, and body temperature)  
x Tanner staging  
x AEs 
x Seizure and medication diary review 
x C-SSRS (since previous visit).  Only for patients â‰¥ 7 years old if appropriate, otherwise 
clinical judgement will be used. 
7.3. Study Procedures (Part B:  OLE Period) 
7.3.1. First OLE Visit (Visit 5, Week 12) 
Patients who complete Part A with a seizure reduction of â‰¥ 35% compared to the [ADDRESS_64733] any other c ontraindications for continued treatment will 
continue to be treated with GNX in the OLE period (Part B) of the study.  Ganaxolone patients 
will continue GNX treatment at the dose that they were on at the completion of Part A.  The 
following study procedures/assessments will be co mpleted during the final maintenance period 
visit in Part A (Visit 5, Week 12): 
x Confirm patient OLE eligibility ( â‰¥ 35% reduction in seizure frequency)  
x Vital signs (to include BP, HR, RR, and body temperature). 
x Height and weight.  Length will be measured if height cannot be obtained. 
x Physical, neurological, and developmental examination (developmental examination is 
limited to pediatric patients 2 to 17 years of age, inclusive) 
x ECG 
x Clinical laboratory tests (chemistry and hematology) 
x Urinalysis 
x Drug screen (plasma) for THC and CBD 
x Serum pregnancy test for all girls/women of childbearing potential  
x IP Population PK sample (drawn when convenient during the visits) 
	
		
 
Confidential  Page [ADDRESS_64734] of care 
x  
x AEs 
x Seizure and medication diary review 
x  
x CGI-C (parent/caregiver/LAR identified behavioral target) 
x CGI-I (parent/caregiver/LAR and clinician) 
x C-SSRS (since previous visit).  Only for patients â‰¥ 7 years old if appropriate, otherwise 
clinical judgement will be used. 
x Dispense IP 
7.3.2. OLE Period and Final OLE Visit or Taper Visit (Visits 6, 7, and 8 [or Early 
Discontinuation], Weeks 20, 28, and 36 [or Early Discontinuation] Â± 7 days) 
The following study procedures/assessments will be completed during the OLE period of the 
study at Visits 6, 7, and 8 (Â± 7 days): 
x Vital signs (to include BP, HR, RR, and body temperature) 
x Weight 
x Physical, neurological, and developmental examination (developmental examination is limited to pediatric patients 2 to 17 years of age, inclusive) 
x ECG (Visit 7, Week 28 and Visit 8, Week 36) 
x Clinical laboratory tests (chemistry and hematology) 
x Urinalysis (Visit 7, Week 28 and Visit 8, Week 36) 
x Drug screen (plasma) for THC and CBD (Visit 7, Week 28) 
x Serum pregnancy test for all girls/women of childbearing potential 
x Tanner staging (Visit 8, Week 36) 
x IP PK sample (drawn when convenient during the visits) 
x Concomitant AED review and levels if per standard of care  
x  
x AEs 
x Seizure and medication diary review 
x  
x CGI-C (Visit 8, Week 36, parent/caregiver/LAR identified behavioral target) 
x CGI-I (Visit 8, Week 36, parent/caregiver/LAR and clinician) 
	
		

 
Confidential  Page 58 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x C-SSRS (since previous visit).  Only for patients â‰¥ 7 years old, otherwise clinical 
judgement will be used. 
x Dispense IP 
7.3.3. Telephone Follow-up (Weeks 16, 24 and 32 Â± 7 days) 
A telephone follow-up visit will be conducted at Weeks 16, 24, and 32 (Â± 7 days) of the OLE 
period to assess the following: 
x AEs 
x Seizure and medication diary review 
7.3.4. Safety Follow-up Post Taper (Visit X, [ADDRESS_64735] Dose Â± 3 days) 
The following study procedures/assessments to be completed during the Safety Follow-up Post 
Taper Visit (Â± 3 days): 
x Vital signs (to include BP, HR, RR, and body temperature) 
x Physical, neurological, and developmental examination (developmental examination is 
limited to pediatric patients 2 to 17 years of age, inclusive) 
x Clinical laboratory tests (chemistry and hematology) 
x Urinalysis 
x Serum pregnancy test for all girls/women of childbearing potential 
x IP PK sample (drawn when convenient during the visits) 
x Concomitant AED review and levels if standard of care 
x AEs 
x Seizure and medication diary review 
7.3.5. Unscheduled Visits 
Unscheduled visits can occur between regularly scheduled visits. For patients who are remaining 
in Part B (on the OLE)after Visit 8, unscheduled visits may take place as decided by [CONTACT_10670], but no longer than six months after the prior visit, or prior to exiting the study.  Unscheduled 
Visits assessments will be conducted at the di scretion of the PI. These assessments may include 
vital signs, laboratory testing, etc. 
 
7.4. Screening and Diagnosis 
Potential patients will be pre-identified by [CONTACT_59742] a previous TSC diagnosis based on 
clinical features and/or genetic testing results and those still experience refractory seizures.  
	
		
 
Confidential  Page 59 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
7.4.1. Informed Consent/Assent 
Procedures specific to this protocol and not otherwise considered standard of care, will not be 
performed until written informed consent/assent from the parent/caregiver/LAR has been appropriately obtained.   
7.4.2. Drug Screen 
A drug screen (plasma) will be performed to test for THC and non-approved CBD at Visit 1 
(screening).  If the screening drug test is positiv e, a confirmatory retest, via plasma, will be 
performed after [ADDRESS_64736] duri ng the treatment phase will result in early 
termination. 
7.4.3. Demographics and Medical History 
Demographics including age, gender, ethnicity and race will be collected.  In addition to the 
genetic evaluation of pathogenic or likely pathogenic TSC1/TSC2  variant, relevant medical 
history including but limited to the age of seizure onset, other physical disabilities such as 
scoliosis, visual impairment, sensory problems a nd gastrointestinal difficulties will also be 
assessed.  The patientâ€™ s developmental history will also be assessed.  Demographics and Medical 
History will be reviewed and collected at the Visit 1 (screening).  A review of the patientâ€™s 
Medical History will be performed again at Visit 2 (baseline). 
7.4.4. Genetic Testing 
Genetic testing to assess if the patient has a pathogenic or likely pathogenic TSC1/TSC2  variant 
will be conducted by [CONTACT_456]â€™s central gene tic laboratory if the patient does not have 
previous genetic testing.  Previous genetic testing results are acceptable for review.  
Instructions for genetic testing sample collection and processing can be found in the genetic 
testing laboratory manual. 
7.4.5. Seizure Identification and Diagnostic Review 
Per the inclusion criteria, enrollment into the study will be based on the presence and frequency 
of the primary seizure types.  The primary seizure types are defined as the following:  focal 
motor seizures without impairment of consciousness or awareness, focal seizures with impairment of consciousness or awareness, focal seizures evolving to bilateral, tonic-clonic convulsive seizures, and generalized motor seizures including tonic-clonic, bilateral tonic, bilateral clonic, or atonic/drop seizures.  Focal and generalized nonmotor seizures, infantile or 
epi[INVESTIGATOR_59666], and myoclonic seizures do not count as the primary seizure types.  
To standardize seizure identification and classification in the study, a SIF/DRF will be submitted 
and reviewed by [CONTACT_59743][INVESTIGATOR_55610].   Approval of the SIF/DRF will be required 
prior to IP dosing.   
Instructions for completion of the SIF/DRF can be found in the Investigator Site File. 
7.5. Efficacy Assessments 
Efficacy as determined by a reduction in seizures will be  evaluated by [CONTACT_59744] a seizure diary.  Days in which no seizures occur will also be noted.  
	
		
 
Confidential  Page 60 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Changes in seizure intensity/duration, CGI-I, as well as changes in behavior and neuropsychiatric 
symptoms will be assessed by a variety of clinician and caregiver administered instruments .  
7.5.1. Seizure Type and Frequency 
Parent/caregiver/LAR will record daily seizure fre quency denoting seizure type and frequency in 
a seizure diary.  Primary seizure types of focal motor seizures without impairment of consciousness or awareness, focal seizures with impairment of consciousness or awareness, focal seizures evolving to bilateral, tonic-clonic convulsive seizures, and generalized motor seizures including tonic-clonic, bilateral tonic, bilateral clonic, or atoni c/drop seizures will be counted 
towards the primary endpoint. 
Patients or parent/caregiver/LAR are to record administration of IP and background AEDs in the 
daily seizure calendar.  Compliance with IP treatment will be assessed by [CONTACT_59745]â€™ 
diary/seizure calendar and returned supplies with queries as necessary.  Patients that fall below 
80% compliance at 2 consecutive visits during the maintenance period will not be included in the 
PP population. 
7.5.2. Caregiver Global Impression of Change (CGI-C - Target Behavior) 
The CGI-C in Target Behavior is a 7-point Likert scale in which the caregiver chooses one 
domain from possible domains of sociability, comm unication, irritability, and hyperactivity to 
assess change in target behavior after the initiation of IP relative to baseline (prior to treatment 
with IP).  This domain should be chosen based on behavior the parent/caregiver/LAR identifies 
to be the most impactful.  During the baseline visit, the investigator and parent/caregiver/LAR will decide on a domain and identify the specific behavior that the patient exhibits that denotes 
the domain.  This behavior will be used at subsequent visits to assess change after the initiation of IP.  The scale ranges from 1- very much improved, 2- much improved, 3- minimally improved, 4- no change, 5- minimally worse, 6- much worse, and 7- very much worse. 
Caregiver Global Impressi on of Change - Target Behavior will be  assessed at Baseline (Visit 2, 
Week 0), Visit 4 (Week 5), and Visit 5 (Week 12) in the treatment period (Part A), and will be 
assessed at Visit 8 (Week 36) and the Final Visit or Taper Visit of the OLE period (Part B).
 
7.5.3. Clinical Global Impression â€“ Improvement (CGI-I) 
The CGI-I is a 7-point Likert scale that the parent/caregiver/LAR and clinician uses to rate the change in overall seizure control, behavior, safety and tolerability after initiation of IP relative to baseline (prior to treatment with IP).  The patient will be rated as follows:  1- very much 
improved, 2- much improved, 3- minimally improved, 4- no change, 5- minimally worse, 
6- much worse, and 7- very much worse. 
Clinical Global Impression â€“ Improvement (parent/caregiver/LAR and clinician) will be assessed 
at Baseline (Visit 2, Week 0), Visit 4 (Week 5), and Visit 5 (Week 12) in the treatment period 
(Part A), and will be assessed at Visit 8 (Week 36) and the Final Visit or Taper Visit of the OLE period (Part B). 
7.6. Exploratory Efficacy Assessments 
 
	
		

 
Confidential  Page 61 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
  
 
  
 
 
 
  
 
 
  
7.7. Safety Assessments 
Safety will be  evaluated by [CONTACT_59746].  
7.7.1. Adverse Events 
Details regarding AEs and SAEs are provided in Section 8 . 
7.7.2. Vital Signs 
Vital signs including HR (bpm), RR (breaths/minut e), body temperature (C/F), BP (mmHg) will 
be collected at every clinic visit. 
7.7.3. Height and Weight 
Height will be collected at Visit 1 (screening).  Length will be measure d if height cannot be 
obtained.  Weight will be collected at Visit 1 (screening), Visit 2 (baseline), Visit 3 (Week 1), 
and every clinic visit thereafter, including the Final OLE Visit or Taper Visit and Safety 
Follow-up Post Taper Visit.  
7.7.4. Physical/Neurological/Developmental Examinations 
The full physical examination will include the following systems: 
x General appearance 
x Head (eyes, ears, nose and throat) 
x Cardiovascular 
x Respi[INVESTIGATOR_696] 
x Gastrointestinal 
x Genitourinary 
x Musculoskeletal 
x Endocrine/Metabolic 
x Hematologic/lymphatic 
	
		

 
Confidential  Page 62 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Skin 
x Other systems as appropriate 
The full neurological examination will include: 
x Cranial nerves 
x Motor exam 
x Sensory exam 
x Reflexes 
x Coordination/Cerebellar 
The full developmental examination (applicable only to pediatric patients 2 to 17 years of age, 
inclusive) will include: 
x Speech/language 
 Makes identifiable sounds for specific objects/people 
 Repeats sounds 
 Single words 
 Multiple words 
 Makes a sentence 
 Replies to question in an identifiable sound, single word, multiple word, sentence 
 Other abilities 
x Motor 
 Sits with support 
 Sits independently 
 Crawls 
 Stands with support 
 Stands independently  
 Takes steps with assistance 
 Walks independently 
 Other abilities 
x Social 
 Smiles appropriately to situation 
 Makes eye contact 
	
		
 
Confidential  Page [ADDRESS_64737] be obtained before the patient is enrolled in the treatment period.   
Electrocardiograms will be performed at Visit 2 (baseline), Visit 3 (Week 1), Visit 4 (Week 5), 
and Visit 5 (Week 12) in the treatment period (Par t A), and will be assessed at Visit 7 (Week 28) 
and the Final OLE Visit or Taper Visit in the OLE period (Part B). 
7.7.6. Clinical Laboratory Tests 
Laboratory safety assessments will be collected  at every clinic visit throughout the study to 
monitor patient safety.  Clinical laboratory tests are listed in Section 12.[ADDRESS_64738] for all girls/women of 
childbearing potential.  Local laboratories will be utilized by [CONTACT_30107]. 
The following liver function and eGFR tests w ill be monitored throughout the study as follows.  
x If AST or ALT increases > [ADDRESS_64739] or more during study, the patient will be 
discontinued.  
x Patients with significant renal insufficiency, eGFR < 30 mL/min (calculated using the Cockcroft-Gault formula), will be discontinued if the criterion is met post baseline. 
If any of the criteria above are deemed clinically significant by [CONTACT_093], then the sponsorâ€™s medical monitor should be contact[INVESTIGATOR_530].  
Urinalysis will be conducted at Visit 1 (screening) or Visit 2 (baseline), Visit 3 (Week 1), Visit 4 
(Week 5), and Visit 5 (Week 12) in the treatment period (Part A), and Visit 7 (Week 28), Visit 8 
(Week 36), the Final Visit or Taper Visit, and the Safety Follow-up or Post Taper Visit in the OLE period (Part B). 
An attempt will be made to collect a urine sample at screening in order to perform the 
study-related urinalysis.  Otherwise, the urine sample for the urinalysis can be collected at 
baseline. 
7.7.7. Tanner Staging 
The Tanner scale (also known as the Tanner stages) is a scale of physical development in 
children, adolescents and adults.  The scale defines physical measurements of development based on external primary and secondary sex characteristics .  Patients will be evaluated and rated as 
Tanner I, Tanner II, Tanner III, Tanner IV, and Tanner V.  Tanner staging will occur at Visit 1 (screening) and Visit 5a (only for patients who do not continue into Part B) of the treatment 
period (Part A), and at the Final OLE Visit or Taper Visit (Part B).  
	
		
 
Confidential  Page [ADDRESS_64740] PK 
Please refer to Section 7.8  for additional details regarding PK assessments. 
7.7.9. Concomitant AED Levels 
Concomitant AED levels are not mandatory but will be collected per sitesâ€™ standard of care.  If 
AED levels are available for Visit 1 (screening), Visit 2 (baseline), Visit 3 (Week 1), Visit 4 
(Week 5) and Visit 5 (Week 12), and throughout th e OLE period of the study at the time points 
noted in Table [ADDRESS_64741] be performed at the precise protocol scheduled time.  
Actual sampling time(s) must be accurately recorded in the source document and appropriate 
eCRF. 
One blood sample will be obtained at Visit 4 (Week 5), and Visit 5 (Week 12) in the treatment 
period (Part A), and at Visit 6 (Week 20), Visit 7 (Week 28), Visit 8 (Week 36), Final OLE Visit 
or Taper Visit, and Safety Follow-up Post Taper Visit of the OLE period (Part B).   
A population PK approach addressing the relationship between GNX PK parameters and 
individual characteristics will be implemented at  Visit 4 (Week 5) and Visit 5 (Week 12) in the 
treatment period.  
During Part A: 
x Visit 4 (Week 5):  between [ADDRESS_64742] IP dosing.  
x Visit 5 (Week 12):  between [ADDRESS_64743] IP dosing.  
During Part B: 
There is no specified time to draw the PK sample and can be drawn when convenient during the 
study visit.  Exact time of sample withdrawal and IP intake will be recorded in the eCRF. 
7.8.1. Clinical Pharmacokinetic Blood Sample Collection and Handling Procedures 
Pharmacokinetic blood collection must not deviate from the nominal collection time set forth in the protocol by [CONTACT_726] Â± [ADDRESS_64744]-dose or by [CONTACT_726] Â± [ADDRESS_64745]-dose.  Samples drawn outside these 
parameters will be considered a protocol deviation.  
Please refer to the laboratory manual for processing instructions. 
	
		
 
Confidential  Page [ADDRESS_64746]; it does not ne cessarily have a causal relationship with 
this treatment.  An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product (International Council for Harmonisation [ICH] Guidance E2A March 1995 ).   
All AEs are collected from the time the informed  consent/assent is signed until the defined 
follow-up period.  This includes events occurring during the screening period of the study, 
regardless of whether or not the IP has been administered.  All AEs reported after the initiation 
of IP will be considered treatment-emergent AEs.  Where possible, a diagnosis rather than a list of symptoms should be recorded.  If a diagnosis has not been made, then each symptom should 
be listed individually.  All AEs should be captured on the appropriate AE pages in the eCRF and 
in source documents.  In addition to untoward AEs, unexpected benefits outside the IP indication 
should also be captured on the AE eCRF page. 
All AEs must b e followed to closure (the patientâ€™s health has returned to baseline status or all 
variables have returned to normal ), regardless of whether the patient is still participating in the 
study.  Closure indicates that an outcome is reach ed, stabilization is achieved (the investigator 
does not expect any further improvement or worsening of the event), or the event is otherwise 
explained.  When appropriate, medical tests and examinations are performed so that resolution of event(s) can be documented.
 
8.1.1. Severity Categorization 
The severity of AEs must be recorded during the course of the event, including the start and stop dates for each change in severity.  An event that changes in severity should be captured as a new event.  Worsening of pretreatment events, after initiation of the IP, must be recorded as new AEs (e.g., if a patient experiences mild intermittent dyspepsia prior to dosing of the IP, but the dyspepsia becomes severe and more frequent after the first dose of the IP has been administered, a new AE of severe dyspepsia [with the appropriate date of onset] is recorded on the appropriate eCRF page). 
The medical assessment of severity is determined by [INVESTIGATOR_1477]: 
Mild: A type of AE that is usually transient and may require only minimal treatment or 
therapeutic intervention.  The event does not generally interfere with usual activities of daily living. 
Moderate: A type of AE that is usually alleviated with specific therapeutic intervention.  The event interferes with usual activities of daily living, causing discomfort, but poses no significant or permanent risk of harm to the research patient. 
Severe: A type of AE that interrupts usual activities of daily living, that significantly affects clinical status, or that may require intensive therapeutic intervention. 
	
		
 
Confidential  Page 66 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
8.1.2. Relationship Categorization 
A physician/investigator must make the assessment of relationship between the IP and each AE.  
The investigator should decide whether, in their medical judgment, there is a reasonable possibility that the event may have been caused by [CONTACT_33249].  If there is no valid reason for suggesting a relationship, the AE should be classified as â€œnot related.â€  Otherwise, if there is any 
valid reason, even if undetermined or untested, for suspecting a possible cause-and-effect 
relationship between the IP and the occurrence of the AE, the AE should be considered â€œrelated.â€  The causality assessment must be doc umented in the source document. 
The following additional guidance may be helpful: 
Term Relationship definition 
Related The temporal relationship between the event and the administration of the IP is 
compelling and/or follows a known or suspected response pattern to that product, and 
the event cannot be explained by [CONTACT_3433] e patientâ€™s medical condition, other  therapi[INVESTIGATOR_014], or 
accident. 
Not related The event can be readily explained by [CONTACT_1604], such as the patientâ€™s underlying 
medical condition, concomitant therapy, or accident, and no plausible temporal or 
biologic relationship exists between the IP and the event. 
8.1.3. Outcome Categorization 
The outcome of AEs must be recorded during the course of the study on the eCRF.  Outcomes are as follows: 
x Fatal 
x Not recovered/not resolved 
x Recovered/resolved 
x Recovered/resolved with sequelae  
x Recovering/resolving 
x Unknown 
8.1.4. Symptoms of the Disease Under Study 
Symptoms of the disease under study should not be classified as AEs as long as they are within the normal day-to-day fluctuation or expected progression of the disease and are part of the 
efficacy data to be collected in the study; however, significant worsening of the symptoms 
should be recorded as an AE.  
8.1.5. Clinical Laboratory and Other Safety Evaluations 
A change in the value of a clinical laboratory, vital sign, ECG assessment can represent an AE if the change is clinically significant or if, during treatment with the IP, a shift of a parameter is observed from a normal value to an abnormal value, or there is a further worsening of an already abnormal value.  When evaluating such changes, the extent of deviation from the reference 
range, the duration until return to the reference ra nge (either while continuing treatment or after 
	
		
 
Confidential  Page 67 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
the end of treatment with the IP), and the range of variation of the respective parameter within its 
reference range must be taken into consideration. 
If, at the end of the treatment period, there are abnormal clinical laboratory, vital sign, or ECG 
values that were not present in the pretreatment findings observed closest to the start of study treatment, further investigations should be performed until the values return to within the 
reference range or until a plausible explanation (e.g., concomitant disease) is found for the 
abnormal values. 
The investigator should decide, based on the above criteria and the clinical condition of a patient, 
whether a change in a clinical laboratory, vital sign, or ECG parameter is clinically significant and therefore represents an AE. 
8.1.6. Pregnancy 
All pregnancies are to be reported from the time informed consent is signed until the defined 
follow-up period. 
Any report of pregnancy for any female study patient or the partner of a male study patient must 
be reported within 24 hours to the Marinus Safety Department or its delegate using the 
Pregnancy Report Form.  A copy of the Pregnancy Report Form (and any applicable follow-up 
reports) must also be sent to the CRO/Marinus medical monitor using the details specified in the emergency contact [CONTACT_59747].  The pregnant female 
study patient must be withdrawn from the study. 
Every effort should be made to gather information regarding the pregnancy outcome and 
condition of the infant.  It is the responsibility of the investigator to obtain this information within 30 calendar days after the initial notification and approximately 30 calendar days after delivery.  
Pregnancy complications such as spontaneous abortion/miscarriage or congenital abnormality 
are considered SAEs and must be reported as outlined in Section 8.2.2 of the protocol using the 
Marinus Clinical Study Serious Adverse Event Form.  Non-serious AEs are to be reported as per clinical eCRF guidelines.  Note:  An elective abortion is not considered an SAE. 
In addition to the above, if the investigator determines that the pregnancy meets serious criteria, 
it must be reported as an SAE to the Marinus Safety Department or delegate as outlined in Section 8.2.[ADDRESS_64747] be reported to the sponsor per the SAE 
reporting procedure whether or not it results in an AE/SAE as described in Section 8.2.2 .  Note:  
The 24-hour reporting requirement for SAEs does not apply to reports of abuse, misuse, overdose, or medication errors unless these result in an SAE.  
The categories below are not mutually exclusive; the event can meet more than 1 category. 
	
		
 
Confidential  Page 68 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Abuse:   Persistent or sporadic intentional intake of an IP for a nonmedical purpose (e.g., 
to alter oneâ€™s state of consciousness or get high) in a manner that may be detr imental to 
the individual and/or society. 
x Misuse:  Intentional use of an IP other than as directed or indicated at any dose.  (Note:  
This includes a situation in which the IP is not used as directed at the dose prescribed by 
[CONTACT_760].) 
x Overdose:  Intentional or unintentional intake of a dose of an IP exceeding a prespecified 
total daily dose of the product.  
x Medication error:   An error made in prescribing, dispensing, administering, and/or use 
of an IP.  For studies, medication errors are reportable to the sponsor only as defined 
below. 
Cases of patientâ€™s missing doses of the IP are not considered reportable as medication errors.  
Medication errors should be collected and reported for the IP under investigation. 
The administration and/or use of an expi[INVESTIGATOR_59696] a reportable medication 
error.  
All IP provided to pediatric patients should be supervised by [CONTACT_7071]/caregiver/LAR. 
8.2. Serious Adverse Event Procedures 
8.2.1. Reference Safety Information 
The reference for safety information for this study is the GNX Investigator's Brochure, which the sponsor has provided under separate cover to all investigators. 
8.2.2. Reporting Procedures 
All initial and follow-up SAE reports must be reported by [CONTACT_59748]/Marinus medical monitor within [ADDRESS_64748] 
awareness of the event.  Note:  The 24-hour reporting requirement for SAEs does not apply to 
reports of abuse, misuse, overdose, or medication errors unless they result in an SAE.  
The investigator must complete, sign, and date the Marinus Clinical Study Serious Adverse 
Event Form and verify the accuracy of the information recorded on the form with the 
corresponding source documents (Note:  Source documents are not to be sent unless requested) 
and fax or e-mail the form to the Marinus Safety Department or its delegate.  A copy of the 
Marinus Clinical Study Serious Adverse Event Form (and any applicable follow-up reports) must 
also be sent to the CRO/Marinus medical monitor using the details specified in the emergency contact [CONTACT_1739]. 
8.2.3. Serious Adverse Event Definition 
An SAE is any untoward medical occurrence (whether considered to be related to IP or not) that 
at any dose: 
x Results in death 
	
		
 
Confidential  Page 69 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
x Is life-threatening .  Note:  The term â€œlife -threateningâ€ in the definition of â€œseriousâ€ refers 
to an event in which the patient was at risk of death at the time of the event; it does not 
refer to an event that hypothetically might have caused death if it were more severe. 
x Requires inpatient hospi[INVESTIGATOR_1081].  Note:  Hospi[INVESTIGATOR_602], which are the result of elective or previously scheduled surgery for 
preexisting conditions that have not worsened after initiation of treatment, should not be 
classified as SAEs.  For example, an admission for a previously scheduled ventral hernia repair would not be classified as an SAE; however, a complication resulting from a hospi[INVESTIGATOR_59697]. 
x Results in persistent or significant disability or incapacity 
x Is a congenital abnorma lity or birth defect 
x Is an important medical event.  Note:  Important medical events that may not result in 
death, be life-threatening, or require hospi[INVESTIGATOR_59698], 
based on appropriate medical judgment, they jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.  Examples of such medical events include allergic bronchospasm requiring intensive 
treatment in an emergency room or at home; blood dyscrasias or convulsions that do not 
result in inpatient hospi[INVESTIGATOR_059]; or the development of drug dependency or drug abuse.  
8.2.4. Serious Adverse Event Collection Time Frame 
All SAEs (regardless of relationship to study) are collected from the time the 
parent/caregiver/LAR signs the informed consen t/assent until the defined follow-up period stated 
and must be reported to the Marinus Safety Department and the CRO/Marinus medical monitor 
within [ADDRESS_64749] awareness of the event.  
In addition, any SAE considered â€œrelatedâ€ to the IP and discovered by [CONTACT_59749] 
[ADDRESS_64750] awareness of the event. 
8.2.5. Serious Adverse Event Onset and Resolution Dates 
The onset date of the SAE is defined as the date the event meets serious criteria.  The resolution 
date is the date the event no longer meets serious criteria, the date the symptoms resolve, or the date the event is considered chronic.  In the case of hospi[INVESTIGATOR_602], the hospi[INVESTIGATOR_59699], respectively. 
In addition, any signs or symptoms experienced by [CONTACT_59750]/assent form or leading up to the onset date of the SAE, or following the resolution date of the SAE, must be recorded as an AE, if appropriate. 
8.2.6. Fatal Outcome 
Any SAE that results in the patientâ€™s death (i.e., the SAE was noted as the primary cause of 
death) must have fatal checked as an outcome, with the date of death recorded as the resolution 
	
		
 
Confidential  Page 70 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
date.  For all other events ongoing at the time of death that did not contribute to the pa tientâ€™s 
death, the outcome should be considered not resolved, without a resolution date recorded. 
For any SAE that results in the patientâ€™s death or any ongoing events at the time of death, unless 
another IP action was previously taken (e.g., the drug was interrupted, reduced, or withdrawn), the action taken with the IP should be recorded as  â€œdose not changedâ€ or â€œnot applicableâ€ (if the 
patient never received the IP).  The IP action of â€œwithdrawnâ€ should not be selected solely as a result of the patientâ€™s death.  
8.2.7. Regulatory Agency, Institutional Review Board, Ethics Committee, and Site 
Reporting 
The sponsor is responsible for notifying the relevant regulatory authorities in the US and the 
CRO is responsible for notifying the relevant regulatory authorities in rest of world of related, 
unexpected SAEs. 
In addition, the sponsor or the CRO is responsible for notifying active sites and central 
institutional review boards (IRBs) of all rela ted, unexpected SAEs  occurring during all 
interventional studies across the GNX program.  
The investigator is responsible for notifying the local IRBs, local ethics committee (EC), or the 
relevant local regulatory authority of all SAEs that occur at their site as required. 
	
		
 
Confidential  Page 71 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
9. DATA MANAGEMENT AND STATISTICAL METHODS 
9.1. Data Collection 
The investigatorâ€™s authorized site personnel must enter the information required by [CONTACT_59751].  A study monitor will visit each site in accordance with the monitoring plan and 
review the eCRF data against the source data for completeness and accuracy.  Discrepancies 
between source data and data entered on the eCRF will be addressed  by [CONTACT_1746].  
When a data discrepancy warrants correction, th e correction will be made by [CONTACT_59752].  Data collection procedures will be discussed with the site at the site initiation visit and/or at the investigatorâ€™s meeting.  Once a patient is screened, it is expected that site personnel will complete the eCRF entry within approximately 7 business days of the patient â€™s visit.  
The patient â€™s parent/caregiver/LAR must enter the information required by [CONTACT_59753].  A study monitor will review all seizure diary entries in accordance with the monitoring 
plan for completeness and accuracy.  Discre pancies will be addressed by [CONTACT_13935] â€™ 
parent/caregiver/LAR and qualified site personnel.  When a data discrepancy warrants 
correction, the correction will be made by [CONTACT_13935] â€™ parent/caregiver/LAR and authorized site 
personnel.  Data collection procedures will be discussed with the site at the site initiation visit and/or at the investigatorâ€™s meeting.  Once the patient â€™s parent/caregiver/LAR signs informed 
consent/assent, it is expected that all diary entries will be made daily and no longer than 48 hours 
after each day. 
Telephone Follow-up visits are allowed to be conducted via secure email per institutional policy 
if granted by [CONTACT_59754]/EC. 
9.2. Clinical Data Management 
Data will be entered into a clinical database as specified in the CRO data management plan.  
Quality control and data validation procedures will be applied to ensure the validity and accuracy 
of the clinical database. 
Data will be reviewed and checked for om issions, errors, and va lues requiring further 
clarification using computerized and manual procedures.  Data queries requiring clarification 
will be communicated to the site for resolution.  Only authorized personnel will make corrections 
to the clinical database, and all corrections  will be documented in an auditable manner. 
9.3. Statistical Analysis Process 
The study will be analyzed by [CONTACT_59755] t.  The statistical analysis plan (SAP) will 
provide the statistical methods and definitions for the analysis of the efficacy and safety data, as 
well as describe the approaches to be taken for summarizing other study information, such as patient disposition, demographics, and baseline characteristics; IP exposure; and prior and concomitant medications.  The SAP will also incl ude a description of how missing data will be 
addressed. 
All statistical analyses will be performed using SAS
Â® (SAS Institute, Cary, NC [ZIP_CODE]) software. 
	
		
 
Confidential  Page 72 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
9.4. Sample Size Calculation and Power Considerations 
Approximately 36 TSC patients, aged 2 to 65 inclusive, will be screened to achieve 30 TSC 
patients enrolled in Part A.  Since this is an OL proof of concept study, sample size was not determined by [CONTACT_59723]. 
9.5. Analysis Populations 
The intent-to-treat (ITT) population comprises all patients who receive at least one dose of IP.  The ITT population will be the primary populati on for efficacy analyses.  The PP population 
includes all ITT patients without major protocol violations (defined prior to database lock).  
Safety will be reported for all patients. 
9.6. Efficacy Analyses 
Since this is an OL proof of concept study, no inferential statistical testing will be conducted.  All efficacy outcomes will be assessed descri ptively with point estimates and 95% confidence 
intervals. 
9.6.1. Primary Efficacy Endpoint 
The primary efficacy endpoint (change in seizure frequency) is the percent change in 28-day 
seizure frequency through the end of the 12-week treatment period (4-week titration and 8-week 
maintenance) relative to the baseline, based on the primary seizure types.  The primary seizure 
types are defined as the following:  focal motor seizures without impairment of consciousness or awareness, focal seizures with impairment of consciousness or awareness, focal seizures evolving to bilateral, tonic-clonic convulsive seizures, and generalized motor seizures including tonic-clonic, bilateral tonic, bilateral clonic, or atonic/drop seizures.  Focal aware non-motor and generalized seizures without motor features, infantile or epi[INVESTIGATOR_59666], and myoclonic seizures do not count as the primary seizure types.  
Post-baseline 28-day seizure frequency will be calculated as the total number of seizures in the 
12-week treatment periods (4-week titration plus 8-week maintenance period) during Part A 
divided by [CONTACT_59756], multiplied by 28.  Baseline 28-day 
seizure frequency will be calculated as the total number of primary seizures in the baseline period divided by [CONTACT_59757], multiplied by 28.   
 
The baseline, post-baseline, and arithmetic and percent changes from baseline in 28-day seizure 
frequency will be summarized using descriptive statistics.  
The percentages of seizure-free days will be  based on the primary seizure types (primary 
seizure-free-days) and infantile/epi[INVESTIGATOR_59666] (infantile/epi[INVESTIGATOR_59700]). 
9.6.2. Secondary Efficacy Endpoints 
In addition to evidence about effects of GNX on 28-day seizure frequency, the clinical trial will 
assess GNXâ€™s effects on several secondary endpoints that capture important symptoms and 
activities of daily living that are m eaningfully compromised by [CONTACT_59758].  The 
behavioral/neuropsychiatric se condary endpoints will provide information about the overall 

	
		
 
Confidential  Page [ADDRESS_64751] of GNX on the treatment of patients with TSC.  The CGI-C and the CGI-I are 7-point 
scales, and the number and percentage of patients with each score will be summarized.  The scores range from 1 = very much improved to 7 = very much worse.  
Derived seizure secondary e fficacy endpoints will be based on data through the end of the 
12-week treatment period relative to the 4-week baseline period.  
[IP_ADDRESS]. Secondary Efficacy:  Seizure control 
x Percentage of patients experiencing a â‰¥ 50% reduction in 28 -day primary seizure 
frequency through the end of the 12-week treatment period compared to the 4-week 
Baseline Period  
[IP_ADDRESS]. Secondary Efficacy:  Other 
x CGI-I, parent/caregiver and clinician 
x CGI-C â€“ Target Behavior 
9.6.3. Exploratory Efficacy Endpoints 
All secondary and
 
 
  
  
  
 
  
 
  
  
  
 
  
 
   
  
 
  
	
		

 
Confidential  Page 74 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
 
9.6.4. Subgr
oup Analyses 
A subgroup analysis of the primary endpoint is not planned at this time. 
9.7. Safety Analyses 
Safety will be reported for all patients.  The results in Part A and Part B will be summarized 
separately and then the combined results in Pa rt A and Part B will be summarized together.  
Adverse events will be tabulated by [CONTACT_59724], system organ class, and Preferred Term using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.  Incidence and percentage of AEs will be presented.  Additional tables, with AEs classified by [CONTACT_59725].  Subset listings will 
be produced for AEs that cause withdrawal and for SAEs.  Clinical laboratory tests (hematology, 
chemistry and urinalysis), vital signs (temperat ure, BP, pulse rate), weight, and ECGs will be 
summarized using descriptive statistics including changes from baseline.  Change in C-SSRS scores where applicable will be determined.  Physical, neurological and developmental examinations will be summarized using number and percentage of patients with abnormalities. 
9.8. Other Analyses 
 and concomitant AED levels w ill be analyz ed according to the SAP. 
9.9. Pharmacokinetic Analyses 
The PK population will include all patients who have received at least [ADDRESS_64752] 1 sample collected and a valid bioanalytical result obtained.   
Pharmacokinetic analyses will be limited to listing of concentrations because sufficient 
concentration-time data will not be available for noncompartmental analyses such as maximum 
plasma concentration (C
max), area under the concentration versus time curve (AUC), or time of 
maximum concentration (t max). 
Pharmacokinetic data from this study may be used for a Population PK analyses to be conducted separately from this study and re ported separately.  Further deta ils will be provided in the SAP. 
9.10. Interim Analysis 
No formal interim analysis is planned. 
	
		

 
Confidential  Page 75 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
10. SPONSORâ€™S AND INVESTIGATORâ€™S RESPONSIBILITIES  
This study is conducted in accordance with current applicable regulations, ICH, and local ethical 
and legal requirements. 
The name [CONTACT_10215]-party ve ndor (e.g., CRO) used in this study will be 
maintained in the investigatorsâ€™ and sponsorâ€™s files, as appropriate.  
10.1. Sponsorâ€™s Responsibilities  
10.1.1. Good Clinical Practice (GCP) Compliance 
The study sponsor and any third party to whom aspects of the study management or monitoring 
have been delegated will undertake their assigne d roles for this study in compliance with all 
applicable industry regulations, ICH GCP Guideline E6(R2) (2016), as well as all applicable 
national and local laws and regulations. 
Visits to sites are conducted by [CONTACT_59759]/or the company 
organizing/managing the research on behalf of the sponsor to inspect study data patientsâ€™ 
medical records, diaries/seizure calendars and eCRFs in accordance with current GCP and the 
respective local and (inter)national government regulations and guidelines.  Records and data may additionally be reviewed by [CONTACT_38917]. 
The sponsor ensures that local regulatory authority requirements are met before the start of the 
study.  The sponsor (or a nominated designee) is responsible for the preparation, submission, and 
confirmation of receipt of any regulatory authority approvals required prior to release of IP for shipment to the site. 
10.1.2. Public Posting of Study Information 
The sponsor, or their designee, is responsible for posting appropriate study information on 
applicable websites such as ClinicalTrials.gov.  Information included in clinical study registries 
may include participating investigatorsâ€™ names and contact [CONTACT_3031].  
10.1.3. Submission of Summary of Clinical Study Report to Competent Authorities of 
Member States Concerned and Ethics Committees 
The sponsor will provide a summary of the clinical study report to the competent authority of the 
member state(s) concerned as required by [CONTACT_38918](s) and to comply with the Community guideline on GCP.  This requirement will be fulfilled within 6 months of the study 
completion date for pediatric studies and within 1 year for non-pediatric studies as per guidance.  
10.1.4. Study Suspension, Termination, and Completion 
The sponsor may suspend or terminate the study, or part of the study, at any time for any reason.  
If the study is suspended or terminated, the sponsor will ensure that applicable sites, regulatory 
agencies, and IRBs/ECs are notified as appropriate.  Additionally, the discontinuation of a registered clinical study that has been posted to a designated public website will be updated 
accordingly. 
	
		
 
Confidential  Page 76 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
10.2. Investigatorâ€™s Responsibilities  
10.2.1. Good Clinical Practice Compliance 
The investigator must undertake to perform the study in accordance with ICH GCP 
Guideline E6(R2) (2016) and applicable regulatory requirements and guidelines. 
It is the investig atorâ€™s responsibility to ensure that adequate time and appropriately trained 
personnel are available at the site prior to commitment to participate in this study.  The 
investigator should also be able to estimate or demonstrate a potential for recruiting the required 
number of suitable patients within the agreed recruitment period. 
The investigator will maintain a list of appropriately qualified persons to whom the investigator 
has delegated significant study-related tasks, and shall, upon request of the sponsor, provide documented evidence of any licenses and certifications necessary to demonstrate such 
qualification.  Curriculum vitae for investigators and sub-investigators are provided to the study 
sponsor (or designee) before starting the study. 
If a potential research patient has a primary care physician, the investigator should, with the 
patientâ€™s consent, inform them of the patientâ€™s participation in the study.  
A coordinating principal investigator (PI) is appointed to review the final clinical study report for multicenter studies.  Agreement with the final clinical study report is documented by [CONTACT_59760] (single-site study) or coordinating PI (multicenter study), in 
compliance with Directive 2001/83/EC as amended by [CONTACT_1772] 2003/63/EC and 
ICH Guidance E3 (1995).  
10.2.2. Protocol Adherence and Investigator Agreement 
The investigator and any sub-investigators must adhere to the protocol as detailed in this 
document.  The investigator is responsible for enrolling only those patients who have met protocol eligibility criteria.  Investigators are required to sign an investigator agreement to 
confirm acceptance and willingness to  comply with the study protocol. 
If the investigator suspends or terminates the study at their site, the investigator will promptly 
inform the sponsor and the IRB/EC and provide them with a detailed written explanation.  The investigator will also return all IP, containers , and other study materials to the sponsor.  Upon 
study completion, the investigator will provide the sponsor, IRB/EC, and regulatory agency with final reports and summaries as required by [CONTACT_59761]. 
Communication with local IRBs/ECs, to ensure accu rate and timely inform ation is provided at 
all phases during the study, may be done by [CONTACT_456], applicable CRO, investigator, or, for 
multicenter studies, the coordinating PI [INVESTIGATOR_59701]. 
10.2.3. Documentation and Retention of Records 
[IP_ADDRESS]. Electronic Case Report Forms (eCRF) 
The eCRFs are supplied by [CONTACT_59762]. 
	
		
 
Confidential  Page [ADDRESS_64753] separate source documentation;  no data will be recorded directly onto the 
eCRF. All data sent to the sponsor must be endorsed by [CONTACT_093]. The clinical research associate (CRA)/study monitor will verify the contents against the source 
data per the monitoring plan.  If the data are unclear or contradictory, queries are sent for corrections or verification of data. 
Incorrect entries must be crossed with a single line as to not obscure the original entry.  
Corrections must be made adjacent to the item to be altered, initialed, and dated by [CONTACT_49131].  Overwriting of this information or 
use of liquid correction fluid is not allowed. 
[IP_ADDRESS]. Seizure and Medication Diaries  
The seizure diaries are supplied by [CONTACT_59763]. 
All data collected and sent to the sponsor must be endorsed by [CONTACT_093]. 
The CRA/study monitor will verify the contents of th e diary data per the monitoring plan.  If the 
data are unclear or contradictory, queries are sent for corrections or verification of data. 
[IP_ADDRESS]. Recording, Access, and Retention of Source Data and Study Documents 
Original source data to be reviewed during this study will include, but are not limited to, the 
patientâ€™s medical file, the patientâ€™s electronic or paper seizure diaries, and original clinical 
laboratory reports.  
All key data must be recorded in the patientâ€™s medical records.  
The investigator must permit authorized representatives of the sponsor; the respective national, 
local, or foreign regulatory authorities; the IRB/EC; and auditors to inspect facilities and to have 
direct access to original source records relevant to this study, regardless of media. 
The CRA/study monitor (and auditors, IRB/EC, or regulatory inspectors) may check the eCRF 
entries against the source documents.  The consent form includes a statement by [CONTACT_59764]/auditor from the sponsor or its representatives, national or local regulatory authorities, or the IRB/EC to have access to source data (e.g., patientâ€™s medical file, appointment books, original laboratory reports, , ECGs, etc.).  
These records must be made available within reasonable times for inspection and duplication, if 
required, by a properly authorized representative of any regulatory agency (e.g., the US FDA, European Medicines Agency, [LOCATION_008] Medicines and Healthcare Products Regulatory 
Agency) or an auditor. 
	
		

 
Confidential  Page [ADDRESS_64754] be maintained according to ICH GCP requirements and may not be 
destroyed without written permission from the sponsor. 
[IP_ADDRESS]. Audit/Inspection 
To ensure compliance with relevant regulations, data generated by [CONTACT_38922], for example, the US FDA (as well as other US 
national and local regulatory authorities), the European Medicines Agency, the [LOCATION_008] Medicines and Healthcare Products Regulatory Agency, other regulatory authorities, the sponsor or its representatives, and the IRB/EC for each site. 
[IP_ADDRESS]. Financial Disclosure 
The investigator is required to disclose any financial arrangement during the study and for 1 year 
after, whereby [CONTACT_38923], or other payments the investigator received from the sponsor.  The 
following information is collected:  any signif icant payments from the sponsor or subsidiaries, 
such as a grant to fund ongoing research, compensation in the form of equipment, or retainer for ongoing consultation or honoraria; any proprietary interest in IP; and any significant equity interest in the sponsor or subsidiaries as defined in 21 Code of Federal Regulations 54 2(b) (1998). 
10.3. Ethical Considerations 
10.3.1. Informed Consent/Assent 
It is the responsibility of the investigator to obtain written informed c onsent/assent from the 
parent/caregiver/LAR for all study patients prior to any study-related procedures, including screening assessments.  As the disease under consideration is a condition for which the patients will not be capable of signing consent/assent for themselves, a parent/caregiver/LAR will be 
required to sign upon identification of the patient for participation.  
All consent documentation must be in accordance with applicable regulations and GCP.  Each 
patientâ€™s parent/caregiver/LAR, as applicable, is requested to sign and date the patientâ€™s informed consent/assent form or a certified translation, if applicable, after they have received and read (or been read) the written patient information and received an explanation of what the study involves, including but not limited to the objectives, potential benefits and risk, inconveniences, and the patientâ€™s rights and responsibilities.  A copy of the informed consent/assent 
documentation (i.e., a complete set of patient information sheets and fully executed signature 
[CONTACT_1787]) must be given to the patientâ€™s parent/guardian/LAR, as applicable.  This document may 
require translation into the local language.  Signed consent forms must remain in each patientâ€™s study file and must be available for verification at any time. 
Site personnel should document providing instruction for and understanding by [CONTACT_31588]/caregiver/LAR of the safe, responsible storage and administration of the oral IP. 
The investigator provides the sponsor with a copy of the consent form that was reviewed by [CONTACT_5040]/EC and received their favorable opi[INVESTIGATOR_1649]/approval.  A copy of the IRB/ECâ€™s written 
favorable opi[INVESTIGATOR_1649]/approval of these documents must be provided to the sponsor prior to the start 
of the study unless it is agreed to and documented (abiding by [CONTACT_59765] 
	
		
 
Confidential  Page 79 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
provisions) prior to study start that another party (i.e., sponsor or coordinating PI) is responsible 
for this action.  Additionally, if the IRB/EC requires modification of the sample patient 
information and consent document provided by [CONTACT_456], the documentation supporting this requirement must be provided to the sponsor. 
10.3.2. Institutional Review Board or Ethics Committee 
It is the responsibility of the investigator to submit this protocol, the informed consent/assent 
document (approved by [CONTACT_38924]), relevant supporting information, and all 
types of patient recruitment information to the IRB/EC for review, and all must be approved prior to site initiation. 
Responsibility for coordinating with IRBs/ECs is  defined in the i nvestigator agreement. 
Prior to implementing changes in the study, the sponsor and the IRB/EC must approve any 
revisions of all informed consent/assent documents and amendments to the protocol unless there 
is a patient safety issue. 
Investigational product supplies will not be released until the CRO has received written IRB/EC 
approval of and copi[INVESTIGATOR_10158]. 
The investigator is responsible for keepi[INVESTIGATOR_1683]/EC informed of the progress of the study and 
of any changes made to the protocol at least once a year.  The investigator must also keep the 
local IRB/EC informed of any SAEs and significant AEs. 
10.4. Privacy and Confidentiality 
All US-based sites and laboratories or entities providing support for this study, must, where 
applicable, comply with Health Insurance Port ability and Accountability Act (HIPAA) of 1996.  
A site that is not a covered entity as defined by [CONTACT_38925]. 
The confidentiality of records that may be able  to identify patients will be protected in 
accordance with applicable laws, regulations, and guidelines. 
After the patientâ€™s parent/caregiver/LAR have consented to take part in the study, the sponsor 
and/or its representatives review the medical records and data collected during the study.  These records and data may, in addition, be reviewed by [CONTACT_2312], including the following:  independent 
auditors who validate the data on behalf of the sponsor; third parties with whom the sponsor may develop, register, or market GNX; national or local regulatory authorities; and the IRB/EC  that 
gave approval for the study to proceed.  The sponsor and/or its representatives accessing the records and data will take all reasonable pr ecautions in accordance with applicable laws, 
regulations, and guidelines to maintain the confidentiality of patientsâ€™ identities.
 
Patients are each assigned a unique identifying number; however, their initials and date of birth may also be collected and used to assist the sponsor in verifying the accuracy of the data (e.g., to confirm that laboratory results have been assigned to the correct patient).  
The results of studies â€”containing patient unique identifying numbers, relevant medical records, 
and possibly initials and dates of birth â€”will be recorded.  They may be transferred to, and used 
in, other countries that may not afford the same level of protection that applies within the 
countries where this study is conducted.  The purposes of any such transfer would include to 
	
		
 
Confidential  Page [ADDRESS_64755] new data analyses to publish or present the study 
results, and to answer questions asked by [CONTACT_1775]. 
10.5. Study Results/Publication Policy 
Marinus will endeavor to publish the results of all qualifying, applicable , and covered studies 
according to external guidelines in a timely manner regardless of whether the outcomes are perceived as positive, neutral, or negative.  Additionally, Marinus adhere s to external guidelines 
(e.g., Good Publication Practices 2) when forming a publication steering committee, which may be done for large, multicenter Phase [ADDRESS_64756] undergo appropriate technical and 
intellectual property review, with Marinus agreement to publish prior to release of information.  
The review is aimed at protecting the sponsorâ€™s proprietary information existing either at the 
commencement of the study or generated during the study.  To the extent permitted by [CONTACT_38927], the PI [INVESTIGATOR_59702] (or share with other authors) the copyright on 
his/her publications.  To the extent that the PI [INVESTIGATOR_10159], joint, or shared rights, the PI [INVESTIGATOR_59703] a perpetual, irrevocable, royalty-free license to make and distribute copi[INVESTIGATOR_59704]. 
The term â€œpublicationâ€ refers to any public disclosure, including original research articles, 
review articles, oral presentations, abstracts and posters at medical congresses, journal supplements, letters to the editor, invited lectures, opi[INVESTIGATOR_10162], book chapters, electronic postings on medical/scientific websites, or other disclosure of the study results, in printed, electronic, oral, or other form. 
Subject to the terms of the paragraph below, the investigator shall have the right to publish the 
study results, and any background information provided by [CONTACT_59766].  Notwithstanding the foregoing, no publication that i ncorporates the sponsorâ€™s 
confidential information shall be submitted for publication without the sponsorâ€™s prior written agreement to publish and shall be given to the sponsor for review at least [ADDRESS_64757] publication of the study results shall be made 
by [CONTACT_10208]â€™s presentation of a joint, multicenter publication 
of the compi[INVESTIGATOR_38865].  If such  a multicenter publication is not submitted to 
a journal for publication by [CONTACT_10209] 18-month period after conclusion, abandonment, or termination of the study at all sites, or after the sponsor confirms there shall be no multicenter study publication of the study results, an investigator may individually publish the study results from the specific site in accordance with this section.  The investigator must, however, acknowledge in the publication the limitations of the single-site data being presented. 
Unless otherwise required by [CONTACT_10210], or the forum in which 
it is made, authorship will comply with the International Committee of Medical Journal Editors 
	
		
 
Confidential  Page 81 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
current standards.  Participation as an investigator does not confer any rights to authorship of 
publications. 
	
		
 
Confidential  Page 82 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
11. REFERENCES 
Bialer M., Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new 
antiepi[INVESTIGATOR_006]: A summary of the Tenth Eilat Conference (EILAT X). Epi[INVESTIGATOR_5612]. 2010;92(2-3):89-124. 
Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, White HS, Wolf HH, 
Mirsadeghi S, Tahir SH, Bolger MB, Lan NC, Gee KW. Characterization of the anticonvulsant 
properties of ganaxolone (CCD 1042; 3alpha-hydroxy- 3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor. J 
Pharmacol Exp Ther. 1997;280(3):1284-95. 
Chu-Shore J, Major P, Camposano S, et al. The natural history of epi[INVESTIGATOR_59705]. Epi[INVESTIGATOR_8330] 2010;51:1236-41. 
Di Michele F, Verdecchia M, Dorofeeva M, et al. GABA
A receptor active steroids are altered in 
epi[INVESTIGATOR_59706]. J Neurol Neurosurg Psychiatry. 2003;74:667-70. 
French JA, Lawson JA, Yapi[INVESTIGATOR_59707]. Adjunctive everolimus therapy for treatment-resistant focal-
onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomized, 
double-blind placebo-controlled study. Lancet. 2016;388:2153-63. 
Ganaxolone Investigatorâ€™s Broc hure. Marinus Pharmaceutic als, Inc., Dated 03 Dec 2019. 
International Council for Ha rmonisation Guidance E2A March 1995. Accessed 20-Feb-2018. 
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/
E2A_Guideline.pdf 
JÃ¼lich K, Sahin M. Mechanism-based treatment in tuberous sclerosis complex. Pediatric Neurol. 
2014;50:290-6. 
Kaminski RM, Livingood MR, Rogawski MA. Allopregnanolone analogs that positively 
modulate GABA receptors protect against partial se izures induced by 6-Hz electrical stimulation 
in mice. Epi[INVESTIGATOR_8330]. 2004;45(7):864-7. 
Kerrigan JF, Shields WD, Nelson TY, Bluestone DL, Dodson WE, Bourgeois BF, Pellock JM, 
Morton LD, Monaghan EP. Ganaxolone for treating intractable infantile spasms: a multicenter, 
open-label, add-on trial. Epi[INVESTIGATOR_5612]. 2000;42(2-3):133-9. 
Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: 
Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus 
Conference. Pediatric Neurol. 2013;49:255-65. 
Laxer K, Blum D, Abou-Khalil BW, Morrell MJ, Lee DA, Data JL, Monaghan EP. Assessment 
of ganaxolone's anticonvulsant activity using a randomized, double-blind, presurgical trial design. Ganaxolone Presurgical Study Group. Epi[INVESTIGATOR_8330]. 2000;41(19):1187-94. 
Ligsay A, Van Dijck A, Kooy RF, and Hagerman R. Ganaxolone in Children with FXS. 
International FXS Conference San Antonio, TX 2016.  
Mizuguchi M, Ikeda H, Kagitani-Shimono et al. Everolimus for epi[INVESTIGATOR_59708]: EXIST-3 substudy in Japan. Brain & Development. 
2019;41:1-10.  
	
		
 
Confidential  Page 83 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: 
Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. Pediatric Neurol. 2013;49:243-54. 
Pi[INVESTIGATOR_59709], Tsai J, Soufflet C, Rey E, Shaw K, Giller E, Dulac O. Clinical evaluation of 
ganaxolone in pediatric and adolescent patients with refractory epi[INVESTIGATOR_002]. Epi[INVESTIGATOR_8330]. 
2007;48(10):1870-4. 
Reddy DS, Castaneda DC, O'Malley BW, Rogawski MA. Anticonvulsant activity of 
progesterone and neurosteroids in progesterone receptor knockout mice. J Pharmacol Exp Ther. 2004;310(1):230-9. 
Reddy DS, Rogwski MA. Neurosteroids â€” Endogenous regulators of seizure susceptibility and 
role in the treatment of epi[INVESTIGATOR_002] (Chapter 77). In, Jasperâ€™s Basic Mechanisms of the Epi[INVESTIGATOR_31629], 
Fourth Edition (Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV, eds.), 
Contemporary Neurology Series 80, Oxford University Press. 2012; pp. 984 â€“1002. 
Sperling MR, Klein P, Tsai J. Randomized, double-blind, placebo-controlled phase 2 study of 
ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures. Epi[INVESTIGATOR_8330]. 
2017;58(4):558-64. 
van der Poest Clement E, Jansen, F.E., Braun, K.P.J. et al. Update on Drug Management of 
Refractory Epi[INVESTIGATOR_59710]. Pediatric Drugs (2020). 
https://doi.org/10.1007/s40272-019-[ZIP_CODE]-0  
 
	
		
 
Confidential  Page 84 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
12. APPENDICES 
12.1. Appendix 1:  CYP3A4/5/[ADDRESS_64758] John's wortf  
conivaptinb  
grapefruit juicec  
indinavir  
itraconazoleb  
ketoconazoleb  
lopi[INVESTIGATOR_054]/ritonavirb (combination drug)  
mibefradild  
nefazodone  
nelfinavir  
posaconazole  
ritonavirb  
saquinavir  
telaprevir  
telithromycin  
voriconazole  
AUC = area under the concentration versus time curve, CYP = cytochrome P450 
a. A strong inhibitor for CYP3A is defined as an inhibitor that increases the AUC of a substrate for CYP3A by â‰¥ 5-fold. 
b. In vivo inhibitor of P-glycoprotein. c. The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent.  Studies 
have shown that it can be classified as a â€œstrong CYP3A inhibitorâ€ when a certain preparation was used (e.g., high dose, double strength) or as a â€œmoderate CYP3A inhibitorâ€ when another preparation was used (e.g., low dose, single strength).  
d. Withdrawn from the [LOCATION_002] market because of safety reasons. e. A strong inducer for CYP3A is defined as an inducer that results in â‰¥ 80% decrease in the AUC of a substrate for CYP3A. 
f. In vivo inducer of P-glycoprotein.   
 
Note:  The list of drugs in these tables is not exhaustive.  Any questions about drugs not on this list should be addressed to 
the medical monitor of the protocol. 
 
Source:  FDA Drug Development and Drug Interactions:  Table of Substrates, Inhibitors and Inducers.  Web link Accessed 
21 Jan 2015:  
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.ht
m#inVivo 
	
		
 
Confidential  Page 85 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
12.2. Appendix 2:  Clinical Laboratory Tests 
Clinical Chemistry  Hematology  Urinalysis  
Total Bilirubin Hemoglobin pH 
AST (SGOT)1 Hematocrit Color 
ALT (SGPT)2 Erythrocytes Clarity 
BUN3 Leukocytes + differential Specific Gravity 
Glucose Thrombocytes (platelet count) Urobilinogen 
Potassium Drug screen5 Ketones 
Sodium Protein 
Calcium Glucose 
Alkaline Phosphatase Bilirubin  
Chloride Blood  
Creatinine Leukocyte esterase 
CO 2 Nitrite  
eGFR4  
  
Quantitative serum E-human 
chorionic growth hormone 
(E-HCG) serum pregnancy  
1AST = aspartate aminotransferase, SGOT = serum glutamic oxaloacetic transaminase 
2ALT = alanine aminotransferase, SGPT = serum glutamic pyruvic transaminase 
3BUN = blood urea nitrogen 
4eGFR = estimated glomerular filtration rate 
5Plasma drug screen for THC, CBD 
  
	
		
Confidential Page 86 of 88IND 044,020 Marinus Pharmaceuticals, Inc.
Protocol 1042-TSC-2001 11 Jun 2021
12.3. Appendix 3:  Dosing Instructions for Oral Suspension
GANAXOLONE 1042-TSC-2001 STUDY
DOSING INSTRUCTIONS FOR ORAL SUSPENSION 
(OPEN-LABEL DOSE TITRATION, OPEN-LABEL MAINTENANCE, OPEN-LABEL 
EXTENSION, AND TAPER)
Name: ________________________________________________________ 
Next Appointment:  _______________________________________________ 
These are your dosing instructions for Ganaxolone Oral Suspension from ____ / _____ / _____ (start date) to ____ / _____ / _____ (end date), until your next visit.  
Take the study medication three times each day with a meal or snack, plus an 8 oz glass of water.
Example 1:
For a 15 kg child, please dose the following:
Dose Titration / Dose Maintenance / Dose Extension/Dose Taper (Please circle study period)
Date___/___/___ to Date ___/___/___Dose 
(mg/kg)Number of mls to take at 
EACH DOSE x 3 
TIMES/DAY
9/23/18 -9/29/18; Days 1-7 6 1.8
9/30/18 -10/6/18; Days 8-14 11 3.3
10/7/18 -10/13/18; Days 15-21 16 4.8
10/14/18 -10/20/18; Days 22-28 21 6.3
Example 2:
For a 15 kg child, please dose the following:
Dose Titration / Dose Maintenance / Dose Extension/ Dose Taper (Please circle period)
Date___/___/___ to Date___/___/___ Dose 
(mg/kg)Number of mls to take at 
EACH DOSE x 3 
TIMES/DAY
10/21/18 to 1/20/19 21 6.3
Dose Titration /
 DoseTitration
/ Dose Maintenance / 
Dose Maintenance /

	
		
 
Confidential  Page 87 of 88  IND 044,020   Marinus Pharmaceuticals, Inc. 
Protocol 1042-TSC-2001  11 Jun 2021 
Please take the study medication as ou tlined below: 
 
Dose Titration / Dose Maintenance / Dose Extension / Dose Taper (Please circle study period) 
 
Date___/___/___ to Date___/___/___  Dose 
(mg/kg)  Number of mls to take at 
EACH DOSE x 3 
TIMES/DAY 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 
SHAKE THE BOTTLE WELL BEFORE DISPENSING 
 
Prior to each dose, the following instructions s hould be followed: 
1. Manually shake bottle end to end, 2 to 3 times per second, for 1 minute 
2. Allow the bottle to stand for 1 minute 
3. Attach the dosing apparatus (adaptor with syringe), invert the bottle and remove the indicated 
dose 
4. Administer dose as indicated 
Use the dosing syringe provided.  Do not use a household spoon.   A new dosing syringe and adapter 
should be used every day.  Dosing syringes should be cleaned with hot water rinse and air-drying between 
first, second, and third daily doses.  
 
	
		
 
Confidential  Page [ADDRESS_64759] udy medication. 
 Study medication should be stored at room temperature (59Â°F-77Â°F/15Â°C-25Â°C) in a safe place.   Save all empty, partially used and unused bottles of the investigational product and return the bo ttles at 
your next visit.  
 
Some people may report feeling dizzy or tired, or experiencing other problems after taking the study 
medication, ganaxolone.  These side effects usually go away after [ADDRESS_64760] your study doctor at the telephone number below to see if a dose adjustment is necessary. 
 
Study Doctor: ________________________________________________________  
 
Telephone Number:  ___________________________________________________  
 
	
		
Certificate Of Completion
Envelope Id: FAF5E8829E3D415081B1E865796694DA Status: Completed
Subject: Please DocuSign: 1042-TSC-2001 Ganaxolone Ph 2 Protocol Amdt 2_Final_2021-06-11.pdfSource Envelope: Document Pages: 88 Signatures: 1 Envelope Originator: Certificate Pages: 1 Initials: 0AutoNav: EnabledEnvelopeId Stampi[INVESTIGATOR_007]: EnabledTime Zone: (UTC-05:00) Eastern Time (US & Canada)[ADDRESS_64761]
Suite 500Radnor, PA  [ZIP_CODE]
IP Address:
Record Tracking
Status: Original
             6/14/2021 9:57:49 AMHolder: 
             Location: DocuSign
Signer Events Signature [CONTACT_59771]: Email, Account Authentication 
(None)Signature [CONTACT_59772]: Drawn on Device
Using IP Address: Sent: 6/14/2021 10:00:50 AM
Viewed: 6/14/2021 1:34:26 PM Signed: 6/14/2021 1:34:[ADDRESS_64762] and Signature [CONTACT_59773]: 
      Not Offered via DocuSign
In Person Signer Events Signature [CONTACT_59774]/Encrypted 6/14/2021 10:00:50 AM
Certified Delivered Security Checked 6/14/2021 1:34:26 PMSigning Complete Security Checked 6/14/2021 1:34:32 PM
Completed Security Checked 6/14/2021 1:34:32 PM
Payment Events Status Timestamps[COMPANY_003]